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Toxicity of Radiotherapy
in Patients With Collagen
Vascular Disease
Alexander Lin, MD,1 Eyad Abu-Isa, MD,1 Kent A. Griffith, MPH, MS2
Edgar Ben-Josef, MD1
1
2

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
University of Michigan Cancer Center Biostatistics Core, Ann Arbor, Michigan.

The following article is reprinted with permission from John Wiley & Sons, Inc. It was
originally published in CANCER, Volume 113, No. 3, pages 648-653, August 1, 2008.

Background
A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The
objective of the current study was to identify factors that influence RT toxicity in the setting of CVD.

Methods
A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD
subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13
patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondylitis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis
(3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with
CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (±2 Gray), and
age (±5 years).

Results
There was no significant difference between CVD patients (65.1%) and controls (72.5%)
experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs
14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079).
RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis
had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma
carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of
severe acute and late toxicity.

Conclusions
Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late
toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater
risk of severe toxicity. These issues should be considered when deciding whether to offer RT for
these patients. Cancer 2008;113:648–53. ©2008 American Cancer Society.

Key Words: radiotherapy, collagen diseases, complications, adverse effects.
The decision of whether to offer therapeutic radiotherapy (RT) to patients with collagen vascular
disease (CVD) continues to be a challenging one. It is believed that CVD may predispose patients
to increased toxicity, and many practicing oncologists believe that a diagnosis of CVD is a relative
contraindication to RT. However, to our knowledge, the available literature on this issue has been
mixed. Early publications were largely case reports of CVD patients with increased toxicity from
RT.1-8 However, 2 separate matched control studies failed to observe any increased risk of acute
or late complications in patients with CVD versus patients without CVD.9,10 Other publications
suggested that patients with nonrheumatoid arthritis CVD,11,12 or patients with specific subtypes of
CVD, may be at increased toxicity risk.13-15 Further complicating the issue is the finding that some
commonly prescribed medications, many of which are used in patients with CVD, may alter the
radiation toxicity profile.16–18 The goals of this matched control study were to determine whether
patients with CVD were at a higher risk of RT-associated toxicity compared with patients without
CVD and to identify factors that influence radiation toxicity in the setting of CVD, with particular
emphasis on medications (antirheumatic drugs, nonsteroidal antiinflammatory drugs [NSAIDs], statins,
and calcium channel blockers [CCBs]) that when taken concurrently may alter radiation toxicity.

Materials and Methods
After Institutional Review Board approval,
101 patients with a diagnosis of CVD treated
in the Department of Radiation Oncology at
the University of Michigan between 1985 and
2005 were identified. A total of 116 unique
RT courses were delivered to these patients. A
majority of these courses were delivered with
3-dimensional (3D) conformal techniques.
Twenty-two cases were excluded because the
diagnosis of CVD was made after the completion of RT. Of the remaining 94 RT courses, 8
courses could not be matched with a control.
This left an analyzable sample of 86 CVD RT
courses for 73 unique patients. Thirty-three
patients had rheumatoid arthritis (RA), 13
had systemic lupus erythematosus (SLE), 9
had scleroderma, 5 had dermatomyositis/polymyositis, 4 had ankylosing spondylitis, 4 had
polymyalgia rheumatica/temporal arteritis,
3 had Wegener granulomatosis, and 2 had
mixed connective tissue disorders (MCTD)/
other. Neither polymyalgia rheumatica/temporal arteritis nor Wegener granulomatosis
are defined as a CVD; however, their inclusion
was based on the systemic vasculitis noted with
these diseases and its potential impact on RT
toxicity. The mean age of the patients at time
of RT was 58.2 years (range, 23-84 years) and
the majority of patients were women (73.3%).
Sixty patients received only a single RT course,
with 13 patients receiving 2 RT courses in this
dataset. Their medical records were reviewed
for the following characteristics: age, sex, race,
CVD type and activity, date of CVD diagnosis,
concurrent medications, cancer diagnosis,
chemotherapy treatment details, site and dose
schedule of RT, acute and late toxicity, pattern
of failure, and survival.
Of the total 86 RT courses, 15 were delivered
to the thorax, 14 to the skin, 12 to the head and
neck, 11 to bone, 11 to the pelvis, 8 to the breast,
6 to total body, 4 to the central nervous system,
4 to the abdomen, and 1 to an extremity.
Each CVD patient was then matched with a
control patient without CVD for sex, race,
site of disease treated by RT, dose delivered
(±2 Gray [Gy]), and age at time of RT delivery
(±5 years). For CVD patients with many
matching controls, the controls with the smallest
difference with regard to RT dose and age at
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RT were chosen, with importance placed on minimizing the difference in
RT dose over the difference in age at RT. An attempt was made to find
3 matching controls for each CVD RT course. Fifty-nine courses were
matched to 3 controls, 18 courses were matched to 2 controls, and 9
courses were matched to a single control.

Late Toxicity
Overall, patients with a CVD diagnosis had a significantly higher
incidence of any late toxicity (29.1% vs 14%; P =.001), with a trend toward
increased severe late toxicity (9.3% vs 3.7%; P =.079) (Table 1).

Acute toxicity was defined as toxicity from the time of commencement of
RT through Day 90 after treatment and was scored using the Radiation
Therapy Oncology Group (RTOG) common toxicity criteria.19 Late
toxicity was defined as occurring after Day 90 posttreatment, and was
scored according to the RTOG/European Organization for Research and
Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20
Severe acute or late toxicity was defined as ≥grade 3.

Table 2. Acute and Late Toxicity by Anatomic Site of
Radiotherapy Delivery

Because this is a match-pairs, case-control analysis, conditional logistic
regression techniques were used. Because sex, age at RT, anatomic site
treated, and RT dose were matched for by the design, these covariates
were not adjusted for in the modeling process because their impact has
been adjusted for by the study design. The remaining covariates of interest
were as follows: concurrent infusional chemotherapy administration, and
the use of steroids, NSAIDS, statins, CCBs, antimalarial antirheumatic
drugs, and oral cytotoxic antirheumatics. Many of the medications apply
only to the CVD cases and could not be adjusted for in the overall model.
The medication list is therefore most appropriately used to help predict
toxicity in the CVD group separately.
Overall crude rates for toxicity are reported by the anatomic site of RT
delivery and by CVD subtype of the cases. Although these rates are
instructive, formal comparison at the matched case-control level has not
been attempted because of the small sample size. Formal comparisons
were limited to the entire population. P values ≤.05 are considered
statistically significant.

Frequency
(Percent)
0

1

2

3

4

5

11 (100.0)
20 (71.4)

0
4 (14.3)

0
4 (14.3)

0
0

0
0

0
0

Breast
Cases (n = 8)
Controls (n = 20)

1 (12.5)
0

1 (12.5)
6 (30.0)

4 (50.0)
14 (70.0)

2 (25.0)
0

0
0

0
0

Head and neck
Cases (n = 12)
Controls (n = 32)

0
5 (15.6)

4 (33.3)
8 (25.0)

6 (50.0)
12 (37.5)

2 (16.7)
7 (21.9)

0
0

0
0

Pelvis
Cases (n = 11)
Controls (n = 28)

0
2 (7.1)

1 (9.1)
7 (25.0)

6 (54.6)
16 (57.1)

4 (36.4)
3 (10.7)

0
0

0
0

Skin
Cases (n = 14)
Controls (n = 35)

0
1 (2.9)

10 (71.4)
17 (48.6)

4 (28.6)
14 (40.0)

0
3 (8.6)

0
0

0
0

Thorax
Cases (n = 15)
Controls (n = 41)

6 (40.0)
14 (34.2)

3 (20.0)
12 (29.3)

6 (40.0)
8 (19.5)

0
7 (17.1)

0
0

0
0

Other Sites†
Cases (n = 15)
Controls (n = 38)

12 (80.0)
19 (50.0)

0
9 (23.7)

3 (20.0)
6 (15.8)

0
4 (10.5)

0
0

0
0

Bone
Cases (n = 11)
Controls (n = 28)

There were 4 endpoints of interest: any acute toxicity, severe acute
toxicity, any late toxicity, and severe late toxicity.

Results
Acute Toxicity
With a median follow-up time of 1.3 years for each group, overall, there
was no significant difference noted with regard to the incidence of acute
toxicity between CVD and control cases, with 65.1% of CVD patients
experiencing any acute toxicity, compared with 72.5% of control patients
(Table 1). The incidence of severe acute toxicity was similar in both
groups (10.5% vs 10.4%).

Table 1. Acute and Late Toxicity by CVD Status
Any Severe

Toxicity Grade
Frequency
(percent)

0

1

2

3

4

5

P†

P†

Acute Toxicity*
CVD cases

30 (34.9) 19 (22.1) 28 (32.6) 9 (10.5)

0

0

—

—

Control Cases

61 (27.5) 63 (28.4) 75 (33.8) 23 (10.4)

0

0

.97

.075

Late Toxicity‡
CVD cases
Control Cases

61 (70.9) 10 (11.6) 7 (8.1)

4 (4.7) 2 (2.3)

2 (2.3)

—

—

191 (86.0) 14 (6.3)

7 (3.2) 1 (0.5)

0

.0010

.079

9 (4.1)

CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and
was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
†
‡

4

Exact P value was derived from conditional logistic regression analysis.
Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to
the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
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Acute toxicity grade*

Late toxicity grade‡
0

1

2

3

4

5

Bone
Cases (n = 11)
Controls (n = 28)

11 (100.0) 0
27 (96.4) 1 (3.6)

0
0

0
0

0
0

0
0

Breast
Cases (n = 8)
Controls (n = 20)

5 (62.5)
13 (65.0)

1 (12.5)
4 (20.0)

2 (25.0)
3 (15.0)

0
0

0
0

0
0

Head and neck
Cases (n = 12)
Controls (n = 32)

6 (50.0)
24 (75.0)

2 (16.7)
2 (6.3)

2 (16.7)
2 (6.3)

2 (16.7)
3 (9.4)

0
1 (3.1)

0
0

Pelvis
Cases (n = 11)
(9.1)
Controls (n = 28)

4 (36.4)

2 (18.2)

1 (9.1)

1 (9.1)

2 (18.2)

1

21 (75.0)

2 (7.1)

3 (10.7)

2 (7.1)

0

0

Skin
Cases (n = 14)
Controls (n = 35)

10 (71.4) 4 (28.6)
35 (100.0) 0

0
0

0
0

0
0

0
0

Thorax
Cases (n = 15)
Controls (n = 41)

11 (73.3)
36 (87.8)

1 (6.7)
4 (9.8)

2 (13.3)
1 (2.4)

1 (6.7)
0

0
0

0
0

14 (93.3)

0

0

0

0

1

36 (94.7)

0

0

2 (5.3)

0

0

Other Sites†
Cases (n = 15)
(6.7)
Controls (n = 38)

CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment,
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
†
‡

Other sites included the abdomen, central nervous system, extremities, and total body.
Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the
RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20

Radiotherapy

Table 3. Distribution of Toxicity (Percent) by CVD Case/Control Status, by CVD Subtype
Late†

Acute*
Any

Severe

Any

Severe

CVD Subtype

CVD

Control

CVD

Control

CVD

Control

CVD

Control

Rheumatoid arthritis

64.9

76.2

10.8

9.9

29.7

13.9

2.7

4.0

Systemic lupus erythematosus

88.2

76.2

29.4

11.9

41.2

19.1

35.3

4.8

Dermatomyositis/polymyositis

66.7

91.7

0

8.3

16.7

8.3

0

0

Ankylosing spondylitis

0

0

0

0

0

0

0

0

Wegener granulomatosis

100

100

0

16.7

33.3

33.3

0

0

Scleroderma

30.0

53.9

0

11.5

20.0

15.4

10.0

3.9

Polymyalgia rheumatica/temporal arteritis

85.7

80.0

0

10.0

28.6

5.0

0

5.0

Mixed connective tissue disorder/other

50.0

83.3

0

16.7

50.0

16.7

0

0

CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
†
Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20

Toxicity by Irradiated Site
Although overall there was no significant difference noted with regard
to the incidence of acute toxicity, CVD patients treated with RT to
some anatomic sites were found to have a higher rate of severe acute
toxicity (Table 2). RT to CVD patients produced higher crude rates of
grade 3 acute toxicity when delivered to the breast (2 patients [25%]
vs 0 patients [0%]) or pelvis (4 patients [36%] vs 3 patients [11%]).
For the 2 CVD patients with severe breast acute toxicity, toxicity
consisted of grade 3 skin desquamation. For the 4 CVD patients with
severe pelvic acute toxicity, 3 had grade 3 skin desquamation alone,
whereas the fourth patient had grade 3 skin desquamation, cystitis,
and diarrhea/dehydration. However, given the small sample sizes
per group and the matched case-control design of the study, formal
statistical comparisons were not attempted.
RT to several anatomic sites produced a higher crude rate of any
late toxicity in CVD patients (Table 2), including the head and neck
(6 patients [50%] vs 8 patients [25%]), pelvis (7 patients [64%] vs
7 patients [25%]), skin (4 patients [29%] vs 0 patients [0%]), and
thorax (4 patients [27%] vs 5 patients [12%]). The incidence of severe
toxicity was greater mainly only in the pelvis subgroup, with 4 CVD
patients (36%) experiencing grade 3+ toxicity (consisting of small bowel
ulceration and dysuria), including 1 grade 5 event (intestinal perforation),
versus 2 in the control group with severe toxicity (7%). RT to the other
anatomic sites was found to be equally well tolerated by both CVD and
control patients.
Toxicity by CVD Subtype
Table 3 summarizes the toxicity information when separated by CVD
subtype. The only patients who had an appreciably higher crude incidence
of any acute toxicity when compared with controls were patients with SLE
(88.2% vs 76.2%). Patients with SLE were also the only CVD subset found
to have a higher crude risk of severe acute toxicity (29.4% vs 11.9%),
which was the highest rate of severe acute toxicity noted among all CVD
subtypes. Otherwise, severe acute toxicity was uncommon.
Compared with controls, the incidence of any late toxicity was observed
to be higher in several CVD subtypes: RA (29.7% vs 13.9%), SLE (41.2%
vs 19.1%), dermatomyositis/polymyositis (16.7% vs 8.3%), polymyalgia
rheumatica/temporal arteritis (28.6% vs 5.0%), and MCTD/other (50.0%
vs 16.7%). The incidence of severe late toxicity was generally low among

both CVD and control patients; however, patients with SLE (35.3% vs
4.8%) and scleroderma (10.0% vs 3.9%) had a higher risk of severe late
toxicity versus controls.

Table 4. Medications and Frequency of Use for CVD Patients
Cases (n = 86)
Medication

Frequency

Percentage

NSAIDs

34

39.5

Corticosteroids

32

37.2

Antimalarials

25

29.1

CCB

20

23.2

Chemotherapy*

18

20.9

Oral cytotoxic, antirheumatic drugs

17

19.8

Statins

13

15.1

CVD indicates collagen vascular disease; NSAIDs, nonsteroidal antiinflammatory drugs; CCB, calciumchannel blocker.
* Concurrent with radiotherapy.

Concomitant Medication Use by CVD Patients
Table 4 lists several types of medications and their frequencies of use
by CVD patients. Tables 5 and 6 list the distribution of acute and late
toxicities for CVD cases, respectively. None of the following medications
was found to be significantly associated with a risk of any acute or late
toxicity: corticosteroids, NSAIDs, statins, CCBs, and antimalarials. The
use of oral cytotoxic, rheumatologic agents was found to be significantly
associated with a decreased risk of any acute toxicity (P = .0263), and
concurrent infusional chemotherapy was found to be significantly
associated with an increased risk of severe acute toxicity (P = .0022).
Chemotherapy was the only concomitant medication that was found to
be associated with increased risk of any (P = .009) or severe (P = .009)
late toxicity.

Discussion
Delivering RT to patients with CVD continues to be a challenging clinical
dilemma for radiation oncologists. The existing literature is difficult to
interpret because of the heterogeneity in CVD subtype and activity, the
variations in RT dose and site of treatment, as well as the potential role
of concomitant medications in altering toxicity. Morris and Powell11
reported that severe late effects were associated with CVD other than
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Table 5.
Medications and Treatments by Acute Toxicity*: CVD Cases Only
Toxicity Grade
Frequency
(percent)
Corticosteroids
No
Yes
NSAIDS
No
Yes
Statins
No
Yes
CCB
No
Yes
Antimalarials
No
Yes
Oral cytotoxics
No
Yes
Infusional
chemotherapy
No
Yes

0

1

22 (40.7)
8 (25.0)

11 (20.4)
8 (25.0)

17 (32.7)
13 (38.2)
28 (38.4)
2 (6.7)
23 (34.9)
7 (35.0)
24 (39.3)
6 (24.0)
20 (29.0)
10 (58.8)

23 (33.8)
7 (38.9)

11 (21.2)
8 (23.5)
13 (17.8)
6 (46.2)
15 (22.7)
4 (20.0)
13 (21.3)
6 (24.0)
16 (23.2)
3 (17.7)

19 (27.9)
0

2
14 (25.9)
14 (43.8)
18 (34.6)
10 (29.4)
23 (31.5)
5 (38.5)
21 (31.8)
7 (35.0)
19 (31.2)
9 (36.0)
25 (36.2)
3 (17.7)

23 (33.8)
5 (27.8)

Any
3
7 (13.0)
2 (6.3)
6 (11.5)
3 (8.8)
9 (12.3)
0
7 (10.6)
2 (10.0)
5 (8.2)
4 (16.0)
8 (11.6)
1 (5.9)

3 (4.4)
6 (33.3)

P†

.17

.65

.13

˜1
.22

.026

.78

Severe
P†

Toxicity Grade
Frequency
(percent)

0

1

2

3

Any Severe
4

5

P†

P†

.47

Corticosteroids
No
Yes

37 (68.5) 6 (11.1)
24 (75.0) 4 (12.5)

5 (9.3) 3 (5.6)
2 (6.3) 1 (3.1)

2 (3.7)
0

1 (1.9)
1 (3.1)

.63

.70

˜1

NSAIDS
No
Yes

37 (71.2) 5 (9.6)
24 (70.6) 5 (14.7)

6 (11.5) 3 (5.8)
1 (2.9) 1 (2.9)

0
2 (5.9)

1 (1.9)
1 (2.9)

˜1

.71

.34

Statins
No
Yes

52 (71.2) 8 (11.0)
9 (69.2) 2 (15.4)

6 (8.2) 3 (4.1)
1 (7.7) 1 (7.7)

2 (2.7)
0

2 (2.7)
0

˜1

˜1

˜1

CCB
No
Yes

47 (71.2) 7 (10.6)
14 (70.0) 3 (15.0)

6 (9.1) 4 (6.1)
1 (5.0) 0

0
2 (3.0)
2 (10.0) 0

˜1

˜1

.44

Antimalarials
No
Yes

45 (73.8) 6 (9.8)
16 (64.0) 4 (16.0)

6 (9.8) 3 (4.9)
1 (4.0) 1 (4.0)

0
2 (8.0)

1 (1.6)
1 (1.0)

.44

.22

.68

Oral cytotoxics
No
Yes

48 (69.6) 7 (10.1)
13 (76.5) 3 (17.6)

7 (10.1) 4 (5.8)
0
0

2 (2.9)
0

1 (1.5)
1 (5.9)

.77

˜1

.0022

Infusional
chemotherapy
No
Yes

53 (77.9) 8 (11.8)
8 (44.4) 2 (11.1)

4 (5.9) 2 (2.9)
3 (16.7) 2 (11.1)

0
1 (1.5)
2 (11.1) 1 (5.6)

.0087

.0089

CVD indicates collagen vascular disease; NSAID, nonsteroidal anti-inflammatory drug; CCB, calciumchannel blocker.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment,
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
†
P value was derived using the Fisher exact test.

CVD indicates collagen vascular disease; NSAIDs, nonsteroidal anti-inflammatory drugs; CCB, calciumchannel blocker.
* Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/
European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20
†
P value was derived using the Fisher exact test.

RA, a finding that was also supported by a meta-analysis by Chon and
Loeffler.12 Other studies suggest that a diagnosis of scleroderma13,14 or
lupus15 may increase the risk of RT associated toxicity. However, 2 separate
matched control studies failed to observe any increased risk of acute or
late complications in patients with CVD versus patients without CVD.9,10

time of RT. We were unable to analyze dose independently as a variable.
Because dose was dependent on treatment site, it would require a range
of RT doses at a given site and a reasonable sample size to make dosespecific comments. This was beyond the scope of our institutional patient
experience. The strengths of this study lie in the total number of patients
analyzed and the use of a 3:1 control:case match by age, sex, RT dose, and
anatomic site. This approach allows for a more robust analysis of the risk
profile, allowing us to determine that patients with scleroderma and SLE
are at increased risk of severe toxicity. Although other CVD subtypes may
also predispose to toxicity, the same conclusions cannot be made because
of the limited sample size of patients with these subtypes in our study. It
is also important to note that with a median follow-up of 1.3 years, the
toxicity rates reported in our study may be underestimating the true rate
of late toxicity. Another unique aspect of this study is the comprehensive
analysis of concomitant medication use and its impact on the RT toxicity
profile. Given the heterogeneity observed in CVD subtype and disease
activity, and other variables such as RT dose and site, it is not likely that
we will ever have prospective controlled data for these questions.

To our knowledge, the current study is the largest matched-control
analysis of acute and late complications in patients with CVDs receiving
RT. Unlike the other matched control studies,9,10 we did find that a
diagnosis of a CVD increased the risk of having any late toxicity, with a
trend toward increased severe late toxicity. We also examined a variety
of factors that can potentially influence the toxicity profile. We found
that there was little difference in toxicity profile for most irradiated
sites. However, RT to the breast and pelvis were possible exceptions.
Greater than one-third of all patients with RT to the pelvis experienced
severe acute and late toxicity. Similar to previous studies,11–15 we also
found that patients with scleroderma or SLE were at the highest risk
of experiencing severe acute or late complications. Morris and Powell11
previously examined the impact of various medications on RT toxicity
and found that patients undergoing NSAID therapy at the time of RT
had a lower risk of late effects. Our findings demonstrated that most
commonly used medications did not influence RT toxicity, but that
concurrent chemotherapy was associated with increased severe acute
and late toxicity.
There are strengths and limitations to the current study. Similar to
previous publications on the subject, we were limited by the heterogeneity
of CVD subtype, which thereby limited the number of patients analyzed
for each subtype. Toxicity data was collected retrospectively, and there
was no reliable method with which to assess CVD activity status at the
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Table 6.
Medications and Treatments by Late Toxicity*: CVD Cases Only
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In summary, although a diagnosis of a CVD appears to predispose patients
to a greater risk of late RT toxicity, treatment is generally well tolerated,
with a relatively low incidence of severe acute or late toxicity. Other factors
can impact the risk of toxicity, including CVD subtype, site of irradiation,
RT dose, and the use of concurrent chemotherapy. In patients who may
be at particularly high risk because of CVD subtype or RT site, careful
attention to issues of toxicity is required. Treatment modifications such as
reduction of fraction size, twice-daily treatment, or reduction of total dose
for these patients may be considered. These factors should be taken into
consideration in the risk-benefit analysis at the time of consultation.

Radiotherapy
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Introduction
Radiation therapy (RT) is delivered after radical prostatectomy (RP) either as salvage treatment for
an elevated prostate-specific antigen (PSA) level1-6 or as adjuvant therapy for patients with highrisk pathologic features7-8. Recent prospective data demonstrated a disease-free survival benefit
of adjuvant RT for pathologic T3N0 prostate cancer9-10. Despite literature supporting the delivery
of post-RP RT to the prostatic fossa (PF), no clear target definition guidelines exist for intensity
modulated radiation therapy (IMRT) or image-guided RT (IGRT)11.
Visualization of the PF is limited on standard CT images, with significant interobserver variability
and uncertainty in CTV definition12. Efforts to incorporate complementary imaging modalities
such as MRI for PF target volume definition have generated neither demonstrably more reliable
PF delineation, nor practical contouring guidelines13. Regardless of the imaging modality, direct
visualization and delineation of the PF clinical target volume (CTV) is fraught with uncertainty.
On the other hand, it is possible to distinguish the borders of important nearby pelvic structures,
namely the bladder and the rectum. The reliability of rectal volume definition on helical CT is
supported by analysis of rectal contours defined in a prospective trial, suggesting the feasibility
of rectal dose-volume data collection in a multicenter setting14. Fiorino et al have described a
correlation between PF CTV shift and anterior rectal wall shift for the cranial half of the rectum in
their report of rectal and bladder movement during post-RP RT using weekly CT images15. These
studies support the reliability of CT-defined rectum contours and a limited correlation between PF
CTV and anterior rectal wall, an important tenet in the current study.
The data reported by Fiorino et al. are limited by the infrequency of image collection and the
acquisition of images at a time and place separate from the treatment couch. Though PTV margin
recommendations are not provided by Fiorino et al., they state eloquently that 1), the anteriorposterior movements of rectum and bladder are more important than lateral motion; 2), the rectum
trends anteriorly during an RT course; 3), there is significant correlation between the posterior
CTV border and the anterior rectal wall for the cranial half of the rectum15. Through the use
of CBCT images obtained during post-prostatectomy RT, the interfraction movement of the
dose-limiting pelvic organs may be characterized further. This information may be used for the
careful extrapolation of information regarding motion of the PF target volume. Prior reports have
described the utility of online CBCT imaging during definitive, primary RT for prostate cancer
using equipment similar to that utilized in the current study16.
In our study, we approach the problem of PF target definition through analysis of real-time
CBCT images during post-RP RT, studying the motion of the critical normal tissue structures
that approximate the anterior and posterior anatomical boundaries of the prostatic fossa. Conebeam CT images, obtained during a definitive course of RT, provided information regarding rectal
and bladder movement. For the purpose of estimating appropriate anterior and posterior PF PTV
definition guidelines, the posterior bladder border and the anterior rectum border were considered
as radiographic surrogates for the anterior and posterior PF borders, respectively.

Methods and Materials
The pelvic anatomy of 10 consecutive prostate cancer patients undergoing post-RP RT was studied
retrospectively using CBCT images obtained during the course of treatment. All patients received a
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radiation dose of 68.4 Gy (1.8 Gy/fraction),
delivered with a four-field conformal RT
plan. Planning CT (CTref) scans, with 3 mm
slice thickness, were obtained in the supine
position with contrast dye cystograms and
urethrograms. Patients were instructed to
follow a strict preparatory regimen before
the CTref and during RT in order to ensure
consistent filling and emptying of the bladder
and rectum, respectively. The attending
physician (R.V.) reviewed and approved
CTV, rectum, and bladder CTref volumes
on the helical CT scans for each patient as
a component of standard RT planning and
delivery. At our institution, a standard 1.0 cm
PTV margin is added to the prostatic fossa
CTV, an empirically chosen guideline. The
standard post-RP treatment policy in our
department includes at least every-other-day
CBCT scans for position verification, with
corrective shifts for 5 mm or more. Image
registration using CBCT scans is performed
based upon bony anatomy including femoral
heads, pubic arch, sacrum, ischium and ilium.
CBCT images were obtained 2-5 times weekly
immediately before treatment using the Elekta
Synergy® cone beam system.
CBCT scans (exported with a 1 mm slice thickness) were registered in relation to the planning
CT using the mutual information algorithm on
the CMS FocalSim®. The automatically co-registered images were evaluated for accuracy by
a single observer (T.S.); manual adjustments

SUP
MID

Bladder

INF

Figure 1. Rectum and bladder motion
were recorded at three points along the
distance from seminal vesicle stump to
bladder-urethral junction.

Radiotherapy

Table 1. Characteristics of 10 patients receiving
radiotherapy to PF after radical prostatectomy
Age (years)
Mean
Range

57
44-69

Time from surgery to RT
Median (months)
≤ 9 months (n)
> 9 months (n)

8.2
6
4

Pre-RT PSA (n)
≤ 0.4
> 0.4

6
4

Gleason Score (n)
GS = 6
GS = 7

2
8

Pathologic Tumor Stage (n)
pT2
pT3

5
5

Extracapsular extension (n)
Yes
No
Margin status
Positive
Negative

Figure 2. Representative cone-beam CT scan obtained on the
treatment couch immediately prior to RT.

6
4
4
6

were made when necessary to produce an optimal fusion of images in
relation to the bony pelvic anatomy. The same observer contoured bladder and rectal volumes on all CBCT images of satisfactory quality for
the identification of the rectal and bladder borders. Rectal and bladder
motion was measured from the seminal vesicle stump (SVS) to the bladder-urethral junction (BUJ) (Figure 1). This region was chosen since
it represents the volume at risk for subclinical disease and it includes
the relevant, potentially dose-limiting organs-at-risk (OAR). For each
patient, 3 cross-sectional levels were studied: 1) superior (SUP), one slice
caudal to the SVS; 2) inferior (INF), one slice cranial to the BUJ; and
3) middle (MID), midway between SUP and INF levels. In the crosssectional plane, midsagittal coordinates were measured at the anterior
rectal border and the posterior bladder border and compared to the planning CT volumes and the mean organ position to obtain interfraction
motion. Lateral shifts were not assessable with this technique, and were
not studied due to minimal impact on RT dose delivered to adjacent
organs at risk (bladder and rectum) relative the anterior and posterior
shifts. Inter-organ distance (IOD), the midsagittal difference between
bladder and rectum, was also recorded at each measurement level, as this
quantity may approximate crudely the anteroposterior PF distance. Data
regarding organ volume and movement were collected for each CTref and
CBCT. The mean and the standard deviation of organ border motion
were calculated relative to both CTref and mean organ position.
In order to assess the reproducibility of the rectum and bladder by volume
definition, repeat contours of the rectum and bladder were performed for 2
patients. In separate contouring sessions, the same observer (T.S.) repeated
the organ definition steps using all CBCT scans for both patients. Repeat
measurements of the anterior rectal border and the posterior bladder
border were recorded, and movement relative to CTref was collected. The
difference between the two sets of CBCT organ contours was calculated
to determine the intraobserver variability for bladder and rectum

Figure 3. Sample treatment planning CT scan (CTref) obtained
prior to initiation of RT.

motion measurements. A similar process was followed for rectum and
bladder volume measurements to determine intraobserver variation in
organ volume.
Anterior and posterior PTV margins were calculated by applying a formula (2Σ + 0.7σ) that includes systematic error (Σ) and random error (σ)
of target volume position17, using measured organ border shifts relative to
CTref for each CBCT scan. Interfraction motion of the posterior bladder
border and the anterior rectum border were used in the analysis as substitutes for anterior and posterior PF motion in order to calculate estimated
margin recommendations.

Results
Ten patients undergoing prostatic fossa RT to 68.4 Gy in 38 fractions were
evaluable for this study. Demographic data is displayed in Table 1. A total of
176 CBCT study sets obtained 3-5 times weekly were analyzed. The rectal
and bladder borders were reliably identified in 166 of 176 (93%) of CBCT
images. Figure 2 shows a representative CBCT image. Figure 3 contains a
typical CT image obtained for planning purposes.
Validation of Methods
Repeat contours and measurements for two patients reveal an average
organ movement measurement discrepancy between contour sets of 1.2 ±
1.7 mm for bladder and 1.1 ± 1.0 mm for rectum for each of thirty CBCT
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Table 2. Organ motion and suggested margin guidelines
based on systematic and random error.
Bladder Motion
(mm)

Observed Motion

Table 3. Pearson correlation coefficients among
mean organ motion and mean organ volume.

Relative to Mean

SUP

MID

SUP

MID

INF

CTref
SD
(+ = anterior,
– = posterior)

+0.1
4.4

+0.4
3.7

+1.5
4.0

INF

-2.6
6.0

-1.6
6.3

-2.7
5.8

Relative to Mean
mean organ SD
position for
all scans
(absolute
values)

3.3
2.9

2.9
2.4

3.1
2.9

4.7
4.6

4.8
4.4

4.5
4.6

Systematic Error (Σ)

2.4

2.1

2.1

3.5

3.5

3.1

Random Error (Σ)

3.3

2.8

2.4

4.0

4.5

3.5

Calculated PTV
Margin (2Σ + 0.7Σ)

7.1

6.2

5.9

9.8

10.2

8.6

study sets analyzed. Average variation at SUP, MID, and INF levels for
bladder was 1.0 ± 1.4 mm, 1.0 ± 1.3 mm, 1.5 ± 2.5 mm, and, for rectum, 1.1
± 1.2 mm, 1.1 ± 0.8 mm, and 1.1 ± 1.1 mm, respectively. Mean difference
in bladder volume between the CBCT contours was 2.4 mL (2.6% of mean
organ volume); for rectal volume, 2.5 mL (4.6% of mean organ volume).
Organ Motion
There was a tendency towards posterior movement of the anterior rectal
wall and anterior tendency in the position of the posterior bladder border
during the RT course relative to the CTref. Organ border motion values at
SUP, MID, and INF levels are displayed in Table 2. The calculated posterior margin for PF PTV creation ranged from 8.6 to 10.2 mm, while the
calculated anterior margin for PF PTV ranged from 5.9 to 7.1 mm (Table
2). The mean IOD observed on CTref images was 8.0 ± 5.7 mm, 6.8 ±
5.1 mm, and 5.6 ± 3.5 mm for the SUP,MID and INF levels, respectively.
The average CBCT IOD, based on mean IOD for all patients, was 11.4
± 6.7 mm, 9.4 ± 3.1 mm, and 10.4 ± 4.2 mm for the SUP, MID and INF
levels, respectively.
Organ Volume
The bladder and rectum CBCT volumes measured during the course of
RT were smaller than those obtained on the planning CT. The average
CTref rectum volume was 67.6 ± 50.5 mL , while the average CBCT volume
was 59.5 ± 11.3 mL (8.1 mL difference). For the bladder, the average CTref
volume was 152.3 ± 103.3 mL, while the average CBCT volume was 93.1
± 26.8 mL (59.2 mL difference). When patients with greater than 50%
difference between CTref and average CBCT organ volume were removed
from analysis (2 patients for bladder and 2 patients for rectum), the mean
difference between average CTref and CBCT volumes decreased to 2.9 mL
for rectum and to 40.7 mL for bladder.
Volume and Motion Relationships
Pearson correlation coefficients were calculated to analyze interrelationships among mean organ motion at SUP, MID, and INF levels, as well as
the average of all levels, mean organ volume, and mean IOD. Correlation coefficient values are displayed in Table 3, revealing that the largest
correlation exists between the anterior rectum border position and the
distance between the rectum and bladder, with a correlation coefficient
of 0.71 between the average interorgan distance and the average rectal wall
position. Figure 4 displays the relationship between rectal motion and
rectal volume.
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Bladder
Volume

Rectum
Volume

IOD

Rectum
Motion

-0.15
-0.01
-0.05
-0.07

0.37
0.25
0.29
0.33

-0.68
-0.56
-0.69
-0.71

X
X
X
X

SUP
MID
INF
AVG

-0.14
-0.14
-0.06
-0.12

0.18
0.17
0.11
0.18

0.29
0.18
0.44
0.10

0.42
0.43
0.23
0.45

IOD
SUP
MID
INF
AVG

0.04
-0.07
0.01
0.01

-0.26
-0.21
-0.26
-0.28

X
X
X
X

X
X
X
X

Rectal Motion
(mm)
Rectum Motion
SUP
MID
INF
AVG

Bladder Motion

Discussion
The normal tissue anatomy (bladder and rectum) adjacent to the PF CTV
was readily definable throughout the course of post-RP RT using CBCT.
Relative to the planning CT, a mean posterior shift of the anterior rectal
wall was observed on the CBCT images. The mean rectal volume as contoured on CBCT images during RT was less than the mean CTref volume.
The rectum border shift and rectal volume change noted in this study
may be related to a trend towards reduced rectal volume over time during
prostate RT18-19. Our adjusted analysis of rectum volumes, which showed
smaller mean variations in rectum volume after the removal of two
large, outlying values, suggests that strict adherence to the bowel preparatory regimen may produce a planning CT that is more representative
of the rectum during RT. The recommendation that patients in the
current study present to clinic for RT with a full bladder and an evacuated rectum may have contributed to the small level of rectum volume
variation observed.
In their study of nine patients receiving weekly CT scans during postRP RT, Fiorino et al report a mean anterior shift of the anterior rectal
wall throughout the cranial half of the rectum, but no shift within the
caudal half of the rectum15. In our study, measurements of rectum and

Figure 4. Scatter plot of rectum motion and change in rectum volume.

Radiotherapy

bladder shifts were performed only at levels that included the PF CTV.
The mean posterior shift of the anterior rectum wall relative to CTref
in the current study (1.6-2.7 mm) was small. The standard deviation
of the rectal wall position on CBCT relative to the CTref (5.8-6.3 mm)
demonstrates important interfraction variation in rectal wall position,
noted throughout the region of rectum relevant to the PF CTV, despite
the small average shift observed. Variations in rectal volume appear to
impact the position of the anterior rectum wall (Figure 4). In addition,
the interorgan distance, which may serve as a rough approximation of the
prostatic fossa, correlates more strongly with anterior rectal motion than
with other factors (Table 3), supporting the influence of rectal border
motion on PF CTV delineation.
We recommend the use of a nonuniform margin for PTV definition,
consisting of a 5.9 to 7.1 mm bladder border margin and an 8.6 to 10.2
mm rectal border margin. A published report of significant correlation
between the anterior rectal wall and the prostatic fossa CTV supports, in
part, the rationale of the current study’s approach, though the reported
relationship between rectal and CTV motion occurred only with the
cranial portion of the rectum15. Although the influence of OAR motion
on PF PTV margin definition seems sensible, the extrapolation of target
information from organ motion should be approached with caution.
The use of 3D conformal RT after RP has been shown to reduce toxicity
relative to conventional delivery techniques20. In addition, rectal dosevolume histograms (DVHs) for patients undergoing post-RP RT have
been shown to correlate significantly with risk for late complications21.
Retrospective analyses of patients undergoing salvage post-RP RT suggest a benefit from RT doses 64.8 Gy or higher2-3. As higher RT doses
are delivered to the prostatic fossa, the ability to minimize toxicity of
adjacent tissues rests upon an understanding of motion of both CTV
and OARs during treatment. Intensity-modulated radiation therapy
(IMRT) may allow safe dose-escalation for post-RP RT22, but its application requires detailed target definition guidelines1. CBCT may allow
tighter RT margins when used to conduct IGRT with daily corrections16,
potentially allowing for higher total doses without parallel increases in
OAR dose and treatment-related toxicity.
The current study provides approximate anterior and posterior margins
for PF PTV definition based on calculations using pelvic organ motion
information. Lateral margins were not calculated, as lateral movement is
less significant than anteroposterior motion9 and is unlikely to influence
dose delivered to the adjacent organs at risk (bladder and rectum). Due to
uncertainty in direct definition of the PF CTV, an indirect approach was
utilized based on interfraction rectal and bladder motion. This approach
acknowledges the uncertainty of CTV definition12, 23 while incorporating
the additional anatomic information provided by on-line CBCT imaging
during the RT course. The bladder and the rectum were easily identified
on most CBCT images in the current study. A small number of CBCT
images collected in the current study (7%) were unusable for organ definition due to poor image quality, which may be attributed to technical
errors in image acquisition. The use of bladder and rectum movements
as determinants for PTV margin guidelines may provide a reliable
approach, as rectal contouring has been shown to be reproducible using
helical CT scans14. These data and similar future studies should be pursued to better define target-definition guidelines for post-RP conformal
RT. Avenues for future applications of CBCT images in post-RP RT may
include daily online localization with manual soft-tissue registration and
subsequent corrective shifts in patient position, as well as off-line adaptive RT based upon a set of CBCT scans obtained during the first week
of RT in a fashion similar to that described previously by Yan et al24. The

current work may be used in future attempts to develop off-line adaptive
strategies for RT that rely upon conformal avoidance of the rectum and
bladder to target the PF CTV for post-prostatectomy patients.
In conclusion, normal tissue anatomy (bladder and rectum) used to define
the anterior and the posterior border of the prostatic fossa was readily definable by CBCT imaging throughout the course of post-RP RT. In
the absence of direct, target-based treatment guidelines available, CBCT
definition of bladder and rectum volumes may be used to pursue anterior
and posterior PTV margin recommendations.
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Purpose
To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron
Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor
(VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts
in nude mice.
Methods and Materials
U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap
(2.5–25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single
dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF
Trap plus fractionated RT were examined.
Results
Improved tumor control was seen when RT (either single dose or fractionated doses) was
combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly
affect the efficacy of combined therapy. Although high-dose VEGF Trap (10 mg/kg or 25 mg/kg)
significantly reduced tumor growth over that of RT alone, there was no additional benefit to
combining high-dose VEGF Trap with RT.
Conclusions
Vascular endothelial growth factor Trap plus radiation is clearly better than radiation alone
in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly
efficacious, it is unclear whether such high doses can be used clinically without incurring normal
tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of
clinical relevance. © 2007 Elsevier Inc.
Key Words: Vascular endothelial growth factor Trap, Radiotherapy, Anti-angiogenic,
U87 glioblastoma.

Introduction
Radiation (RT) therapy is an important treatment modality for many cancers; however, its therapeutic
success is impeded by dose-limiting normal tissue toxicities and the development of radioresistance.
Recent studies emphasize the importance of the tumor microvascular response in addition to the
tumor cell response in determining tumor radioresistance1, 2. Ionizing radiation can directly induce
endothelial cell apoptosis1, 3, which can inhibit tumor growth and lead to radiosensitization. However,
in opposition to endothelial cell damage, radiation also induces signal transduction cascades, which
contribute to radiation resistance through upregulation of proliferative, survival, and angiogenic
pathways4. In particular, radiation induces vascular cytokines, such as vascular endothelial growth
factor (VEGF)5, 6, one of the most potent endothelial cell survival factors7, which functions as a
powerful antiapoptotic factor for endothelial cells in new blood vessels8, 9. Radiation-induced VEGF
results in tumor radioresistance through vascular radioprotection2, 10.
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Inhibition of VEGF activity or disabling the
function of VEGF receptors is therefore a
potential strategy for improving radiation
outcome. The VEGF blockade alone has been
shown to inhibit both tumor growth and
metastasis in a variety of animal tumor models11. Currently, three approaches are in clinical
development to target the VEGF/VEGFR-signaling pathway: (1) monoclonal antibodies
directed against VEGF or its receptors12–15,
(2) small molecule inhibitors of the VEGFR2 tyrosine kinase enzyme16–19, and (3) soluble
decoy receptors created from the VEGFR1
receptor which selectively inhibit VEGF20, 21.
The relative benefits of these strategies have yet
to be determined clinically.
Tumor cures are rare when VEGF blockers
are used as the sole method of treatment; in
general, antiangiogenics appear to work best
in combination with cytotoxic therapies22.
A number of preclinical studies suggest that
radiotherapy in combination with VEGF
targeting agents enhances the radiotherapeutic
ratio (see reviews;23, 24). The best way to incorporate VEGF inhibition strategies into current
radiotherapy regimens remains unknown.
Because of the role that angiogenesis plays in
the radiation response, the objective of this
study was to determine whether VEGF Trap
(Regeneron Pharmaceuticals, Tarrytown, NY),
a potent anti-VEGF angiogenesis inhibitor
that traps circulating VEGF in the bloodstream and in the extracellular space, would
enhance radiation therapy in the human U87
glioblastoma (GBM) tumor model. Because
GBM tumors are among the most radioresistant and vascular of neoplasms and are
known to secrete high levels of VEGF25, U87
GBM was deemed an appropriate model to
assess the effects of VEGF Trap and radiation.
It was hypothesized that inhibition of VEGF
signaling by VEGF Trap would improve the
human U87 glioblastoma model response
to radiotherapy.
The administration of decoy soluble VEGF
receptors has been found to be a very effective
way to block the VEGF signaling pathway26–29.
VEGF Trap is a unique human fusion protein
comprising portions of human VEGF recep-

Radiotherapy

tor 1 (VEGFR1) and human VEGF receptor 2 (VEGFR2) extracellular
domains fused to the constant region (Fc) of human IgG121. VEGF Trap
has greater affinity for the VEGF ligand than anti-VEGF monoclonal
antibodies (mab) do (dissociation constant <1 pMol/L for VEGF Trap
vs. 0.1–10 nMol/L for mab)30. VEGF Trap has been shown to inhibit
neoangiogenesis and tumor growth in tumor xenografts and metastases,
as well as reduce the formation of malignant ascites14, 21, 31.
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Methods and Materials
Analysis of VEGF levels in U87 tumor cells in culture
U87 glioblastoma cells (American Type Culture Collection) were
maintained in alpha MEM (Sigma-Aldrich, St. Louis, MO) with 10%
fetal bovine serum (Atlanta Biologicals, Norcross, GA). U87 cells were
irradiated at doses between 2 and 20 Gy in the presence or absence of
40 nM VEGF Trap and incubated for 48 h. Using a commercially available human VEGF immunoassay kit (R&D Systems, Minneapolis, MN),
VEGF was assayed from culture supernatants.
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Animal and tumor model
U87 cell suspensions (5 x 105 cells in 100 μL phosphate buffered saline)
were implanted subcutaneouly (SC) into the right hind limbs of athymic
NCR NUM mice (Taconic Farms, Hudson, NY). A SC xenograft model
was chosen to facilitate radiation dosing and ease of tumor measurements in the more than 200 mice measured in this study. Mice were not
pretreated before tumor implantation. U87 tumors were allowed to grow
for approximately 14 to 18 days until reaching an approximate diameter
of 4 to 5 mm before treatment.
Drug and irradiation treatment
In an initial pilot study, VEGF Trap was administered at two doses, a high
dose (25 mg/kg) or low dose (2.5 mg/kg), every 3 days, up to 3 weeks,
with or without a single dose of radiation (10 Gy) given on Day 0. VEGF
Trap was administered every 3 days because it has a half-life of 72 h in
mouse serum (drug pharmacokinetics communicated by Regeneron).
Drug was administered 2 h before radiation. When fractionated radiotherapy was used, VEGF Trap was combined at 2.5 mg/kg (low dose)
or 10 mg/kg (intermediate dose) with fractionated radiotherapy (three
fractions of 5 Gy each) on Days 0, 1, and 2. Scheduling of VEGF Trap was
either 1 week before fractionated radiation and continuing for a period
of 3 weeks, concurrent with radiation and continuing for a period of 3
weeks, or 3 days postradiation treatment and continuing for a period
of 3 weeks. Thus, the total number of drug doses was constant for each
schedule (see Fig. 1 for dose and irradiation scheduling protocol).
Irradiation was performed on anesthetized mice using an X-ray machine
(Gulmay Medical, Bethel, CT) operating at 250 kV, 10 mA, with a 2-mm
aluminum filtration. The effective photon energy was ≈90 keV. Mice
were anesthetized with a combination of ketamine and acepromazine at a
concentration of 75 mg/kg and 0.35 mg/kg, respectively. Each mouse was
confined in a lead casing with its tumor-bearing leg extended through
an opening on the side to allow the tumor to be irradiated locally.
Radiation was administered as three daily fractions of 5 Gy each as
described earlier.
Tumor size was measured 4 to 5 times per week after treatment by direct
measurement with calipers and calculated by the formula [(smallest
diameter (2) x widest diameter) / 2]. Tumors were not allowed to grow
beyond 2,000 mm3 in accordance with Institutional Animal Care and Use
Committee regulations.

24

Days
RT (1 day)
RT (3 days)
VEGF Trap (21 Days)

Figure 1. Scheduling protocols for vascular endothelial growth
factor (VEGF) Trap administration in combination with radiation
(RT). VEGF Trap was given at 2.5, 10, or 25 mg/kg every 3 days in
four schedules: (I) VEGF Trap given on Day 0 concurrent with a
single dose of RT (10 Gy) and continued up to 3 weeks; (II) VEGF
Trap given on day –7 before RT (3 x 5 Gy) and continued for 3
weeks; (III) VEGF Trap given on Day 0 concurrent with RT (3 x 5
Gy) and continued up to 3 weeks; (IV) VEGF Trap given on Day 3
post RT (3 x 5 Gy) and continued up to 3 weeks. All three protocols
received the same number of drug doses. Day 0 was always the start
of radiation.

Positron emission tomography imaging
The MOSAIC PET scanner (Philips Medical Systems, Brisbane, CA)
was used for PET studies. Before imaging, mice were anesthetized with
ketamine (75 mg/kg) and acepromazine (0.35 mg/kg) via a SC injection.
Once anesthetized 0.3 to 0.5 μCi of 18-fluorodeoxyglucose (FDG) was
administered intravenously. Sixty to seventy min were allowed for uptake
of the tracer. Mice were placed in a 50-mL specimen tube to facilitate
multimodality stereotactic positioning. The PET data were acquired in
a single position for 15 min. Volumes of interest (VOIs) were defined by
drawing multislice regions of interest (ROIs) on the PET images using
50% of the full-width-at-half-maximum (FWHM) of the tumor to determine the tumor boundary. In the case of tumors with a core lacking FDG
uptake, the tumor and core boundaries were defined by 50% FWHM of
each wall adjacent to the core. Mice were divided into three groups (n
= 3–6 animals per group): untreated; low-dose VEGF Trap–treated (2.5
mg/kg), and highdose VEGF Trap–treated (10 mg/kg).
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Statistical analysis of tumor growth
Tumor size measurements over time were obtained from the following
groups: control; radiation alone; VEGF Trap, low dose (2.5 mg/kg), intermediate dose (10 mg/kg), or high dose (25 mg/kg); and the corresponding two radiation plus VEGF Trap combinations (n = 10–14 animals per
group). Tumor growth over the entire study follow-up period was modeled via mixed-effects linear regression. This approach fits a “random”
growth curve to each animal’s data and then statistically “averages” these
curves within each treatment group to estimate an overall “fixed effect”
for each group. It also properly handles unbalanced data (i.e., different
number of measurements for different animals) and takes into account
the correlation of each animal’s measurements over time. Because tumors
typically grow exponentially, the base-10 logarithm of tumor volume was
modeled as a function of time and treatment. The interpretation of the
linear model for the log of tumor volume is in terms of geometric means
and geometric mean ratios (while the usual interpretation of a regression
model for an untransformed outcome is in terms of arithmetic means and
mean differences). The fitted linear growth curves fitted the data well. In
addition, an allowance was made for the variance of the random effects to
differ across groups to account for the larger variability of measurements
in certain treated groups. All statistical analyses were conducted in SAS
8.2 (SAS Institute, Cary, NC, 1999–2001).
The mixed-effects regression has multiple advantages over analyses of
tumor growth delay that typically compare groups with respect to the
average time it takes tumors to reach some arbitrary size (e.g., 2,000
mm3). First, mixed-effects regression yields more general parameters
of interest, such as average daily tumor growth rate and doubling time.
Second, it can investigate (if necessary) treatment interactions and nonlinear patterns of tumor growth. Finally, it is more efficient because it
used the repeated tumor size measurements obtained over the entire
study period.

Results
Effect of VEGF Trap and radiation on VEGF secretion in U87 cells
in culture
Levels of VEGF increased in U87 culture supernatants in a dose-dependent manner following irradiation (Fig. 2). The addition of VEGF Trap
(40 nM) reduced free VEGF in the supernatant to undetectable levels.
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Immunohistochemistry
Platelet–endothelial cell adhesion molecule 1 (PECAM-1) immunostaining for microvessel density (MVD): control, radiation-treated,
VEGF Trap–treated tumors, and VEGF Trap plus radiation–treated
tumors were immunostained with a rat antimouse PECAM-1 mAb (BD
Biosciences, Boston, MA) and a rabbit antirat biotinylated secondary
antibody (Vector Labs, Burlingame, CA). Enhanced horseradish peroxidase–conjugated streptavidin and a substrate chromogen, AEC
(3-amino-9-ethyl carbazole), were used to visualize the signal. (HISTOSTAIN-PLUS kit, Invitrogen, Carlsbad, CA); slides were examined
with a Nikon Eclipse E600 microscope to calculate MVD, the area
occupied by the PECAM-1-positive microvessels, and total tissue area
per section were quantified using National Institute of Health Image J
software. Microvessel density was expressed as percent area of blood
vessels stained per tissue section. Areas of necrosis were excluded
from calculations. Four or five high-power fields were identified on
each section with three to four sections per tumor and two tumors
per endpoint.
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Figure 2. Effect of vascular endothelial growth factor (VEGF)
Trap and radiation on VEGF secretion in U87 cells in culture. U87
cells were irradiated at doses between 2 and 20 Gy in the presence
or absence of 40 nM VEGF Trap. Cell culture supernatants were
assayed for VEGF secretion 48 h following treatment. VEGF secretion was undetectable in presence of 40 nM VEGF Trap.

Effect of VEGF Trap and radiation on U87 tumor growth inhibition
The linear models for the log-transformed tumor growth fitted the data
quite well in all groups. The raw data for all treatment groups with regression lines are plotted in Figs. 3 through 6 with corresponding Tables 1
through 4. The average daily percent increase in tumor volume for the
untreated control group was consistent across all protocols and ranged
between 27% and 31%, corresponding to a tumor doubling time between
2.5 and 3.0 days (Tables 1–4). Radiation alone (both single or fractionated
doses) or VEGF Trap alone (all doses) significantly reduced the tumor
growth rate compared with control (p < 0.001, Figs. 3–6, Tables 1–4).
Results with VEGF Trap in combination with single dose or fractionated
radiotherapy are now summarized.
Effect of VEGF Trap and single dose radiation (10 Gy) on U87 tumor
growth inhibition
Table 1 presents tumor growth data based on the mixed-effects linear
regression analysis described in Methods and Materials, and Fig. 3 presents the original animal data. In this experiment, a low dose of VEGF
Trap (2.5 mg/kg) initiated concurrently with a single dose of 10 Gy was
compared with a 10x higher dose of VEGF Trap (25 mg/kg) plus 10 Gy.
The six groups are compared in terms of average daily tumor growth
and doubling time. It can be seen from Table 1 and Fig. 3 that both lowdose and high-dose VEGF Trap were effective inhibitors of daily percent
increase in tumor volume (%Δ = 15% and 5%, respectively, vs. 31% for
controls, p = 0.001). Although low-dose VEGF Trap was not significantly
better than 10-Gy treatment alone, the combination of low-dose VEGF
Trap and 10 Gy slowed daily tumor growth (%Δ = 12% vs. 18% for 10
Gy alone and 15% for low VEGF Trap alone). Thus, a less than additive
enhancement in tumor control over either modality alone was observed.
High-dose VEGF Trap, as a single treatment modality, was highly effective in slowing daily percent increase in tumor volume (5% vs. 18% for
10 Gy). Its efficacy was not improved by the addition of 10 Gy. This study
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Figure 3. Effect of vascular endothelial growth factor (VEGF) Trap combined with single-dose radiation (10 Gy) on tumor growth in U87GBM.
Individual mouse data for six treatment groups (n = 10–12 animals per group). VEGF Trap was given at 2.5 or 25 mg/kg starting on Day 0,
concurrent with radiation and continuing every 3 days for 3 weeks (see schedule I, Fig. 1).
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Figure 4. Effect of vascular endothelial growth factor (VEGF) Trap initiated before fractionated radiation (3 x 5 Gy) on tumor growth in U87 GBM.
Individual mouse data for 6 treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day –7 and continuing
every 3 days for 3 weeks (see schedule II, Fig. 2).
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Figure 5. Effect of vascular endothelial growth factor (VEGF) Trap sequenced concurrent with fractionated radiation (3 x 5 Gy) on tumor Growth in
U87 GBM. Individual mouse data for six treatment groups (n = 10–14 animals per group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 0
and continuing every 3 days for 3 weeks (see schedule III, Fig. 3).
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Figure 6. Effect of vascular endothelial growth factor (VEGF) Trap sequenced post–fractionated radiation (3 x 5 Gy) on tumor Growth in U87 GBM.
Individual mouse data for six treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 3 and continuing
every 3 days for 3 weeks (see schedule IV, Fig. 4).
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Table 1. Effect of VEGF Trap combined with single-dose radiation: Summary of tumor growth (Schedule I)
Treatment

%Δ

(95% CI)

T2x

Control (human FC protein)

31.0

(27–35)

2.6

RT (10 Gy)

18.0

(15–21)

4.2

VEGF Trap (2.5 mg/kg)

15.0

(13–28)

4.9

VEGF Trap (25 mg/kg)

5.0

(2–7)

VEGF Trap (2.5mg/kg) + RT

12.0

(9–14)

6.3

VEGF Trap (25 mg/kg) + RT

5.0

(2–7)

15.5

15.2

p values
0.001 vs. control, 0.19 vs. VEGF Trap (low)
0.001 vs. control, 0.19 vs. RT alone
0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGF Trap (low)
0.003 vs. RT, 0.06 vs. VEGF Trap (low)
0.001 vs. RT, 0.417 vs. VEGF Trap (high), 0.96 vs. VEGF Trap (low) + RT

Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).

suggests that low-dose VEGF Trap in combination with single-dose
radiation has an enhanced effect on tumor cell kill. It was thought that
this enhancement might be improved by varying dose and scheduling
protocol. Additional studies were carried out in which low-dose VEGF
Trap at 2.5 mg/kg was compared with an intermediate dose of 10 mg/kg
(because VEGF Trap at 25 mg/kg appeared to have masked any additional benefit of radiation in enhancing tumor control) in combination
with a more clinically relevant fractionated radiotherapy protocol. The
results of these studies are reported in the following sections.
Effect of VEGF Trap and fractionated radiation on U87 tumor growth
inhibition
VEGF Trap given before fractionated radiation: in this protocol, VEGF
Trap was administered 7 days before radiation. The analyses allowed for
separate tumor growth rates in the first and second periods (preradiation:
Days –7 to 0; postradiation: Days 0+) for the groups that received radiation. The study’s main aim was to compare tumor growth rates across treatment groups in the latter period, when all treatments had been applied.
Table 2 summarizes the results of the tumor growth modeling analyses
during this main study phase, and Fig. 4 presents the original animal data.
The low-dose VEGF Trap group (2.5 mg/kg every third day, starting at
Day –7) demonstrated a reduction in daily percent increase in tumor
volume (12% vs. 27% for control; p = 0.001) that was similar to the first
single-dose radiation study, whereas the high-dose VEGF Trap group (10
mg/kg every third day, starting at Day –7) had an even stronger effect
(7%) that, again, was similar in trend to the first study. In the radiation
only group, tumor daily growth was slowed to 11% (p < 0.001 vs. control).
Although low-dose VEGF Trap was comparable to radiation alone (p =
0.59), the combination of low-dose VEGF Trap with radiation (7% average
daily percent increase in tumor volume, Table 1) was significantly better
than either radiation alone (p = 0.036) or low-dose VEGF Trap alone (p
< 0.005). The combination of high-dose VEGF Trap with radiation (5%

average percent daily increase in tumor volume) was also significantly
better than radiation alone (p = 0.002) but not significantly better than high
dose VEGF Trap alone (p = 0.33).
VEGF Trap given concurrently with fractionated radiation: Table 3
summarizes the results of the tumor growth modeling analyses based
on original animal data shown in Fig. 5. High-dose VEGF Trap was
significantly better than radiation in reducing daily percent increase in
tumor volume (8.5% vs. 16.1% for radiation, p = 0.001). The combination of low-dose VEGF Trap with radiation (12% average daily increase
in tumor volume) was significantly better than either radiation alone
(p = 0.029) or low-dose VEGF Trap alone (p = 0.012). The combination
of high-dose VEGF Trap (10 mg/kg) with radiation (7% average daily
increase in tumor volume) was also significantly better than radiation
alone (p = 0.001) but not high-dose VEGF Trap alone (p = 0.417).
VEGF Trap given postradiation: Table 4 summarizes the results of the
tumor growth modeling analyses based on original animal data shown
in Fig. 6. The results of this schedule followed the same pattern as seen
in the previous two schedules with fractionated radiation as well as the
first experiment with single-dose radiation. The benefit of combining
VEGF Trap with radiation compared with single-modality treatments
was once again seen with low-dose VEGF Trap plus radiation. High-dose
VEGF Trap at 10 mg/kg plus radiation significantly reduced percent daily
increase in tumor volume when compared with radiation alone but was
not significantly different from VEGF Trap alone (p = 0.187).
In summary, improved tumor control was seen when radiation (either
single dose or fractionated doses) were combined with the lowest dose
of VEGF Trap (2.5 mg/kg) used in these studies. Scheduling did not significantly affectthe efficacy of combined therapy. The relative benefits
of combined low-dose VEGF Trap plus fractionated radiation relative
to radiation as judged by percent reduction in average daily increase in
tumor volume were 36% for VEGF Trap given before radiation, 27% for

Table 2. VEGF Trap initiated before fractionated radiation: Summary of tumor growth (Schedule II)
Treatment

%Δ

(95% CI)

T2x

Control (human FC protein)

27.0

(23–31)

3.0

p values

RT (3 x 5 Gy)

11.0

(8–15)

6.5

0.001 vs. control, 0.59 vs. VEGF Trap (low), 0.027 vs. VEGF Trap (high)

VEGF Trap 2.5 mg/kg)

12.0

(10-15)

5.9

0.001 vs. control, 0.59 vs. RT

VEGF Trap 10 mg/kg)

7.0

(4–9)

11

0.001 vs control, 0.027 vs. RT, 0.001 vs. VEGF Trap (low)

VEGF Trap (low) + RT

7.0

(4–9)

10.6

0.034 vs. RT, 0.004 vs. VEGF Trap (low)

VEGF Trap (high) + RT

5.0

(2–7)

15.3

0.002 vs. RT, 0.33 vs. VEGF Trap (high)

Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
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Table 3. Trap sequenced concurrently with radiation: Summary of tumor growth (Schedule III)
Treatment

%Δ

(95% CI)

T2x

Control (human FC protein)

27.0

(24–30)

2.9

p values

RT (3 x 5 Gy)

16.0

(13–19)

4.6

0.001 vs. control, 0.729 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)

VEGF Trap (2.5 mg/kg)

17.0

(14–19)

4.5

0.001 vs. control, 0.729 vs. RT alone

VEGF Trap (10 mg/kg)

8.5

(6–11)

8.5

0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)

VEGF Trap (low) + RT

12.0

(9–14)

6.3

0.020 vs. RT, 0.008 vs. VEGF Trap (low)

VEGF Trap (high) + RT

7.0

(5–9)

10.3

0.001 vs. RAD, 0.392 vs. VEGF Trap (high), 0.014 vs. VEGF Trap (low) + RT

Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).

Discussion
concurrent treatment, and 32% for drug given postradiation treatment.
Although high-dose VEGF Trap (either 10 mg/kg or 25 mg/kg) significantly reduced tumor growth over that of radiation alone, there was no
added benefit to combining high dose VEGF Trap with radiation.
Effect of VEGF Trap and radiation on microvessel density
Immunoassaying for endothelial cells with PECAM-1 revealed an inhibition of tumor angiogenesis 3 weeks after treatment with VEGF Trap
or VEGF Trap and radiation. Tumor MVD was similar in the control
and radiation-treated tumors. Tumor MVD in the VEGF Trap treated
tumors was decreased to between 43% to 57% of control or radiationtreated tumors (p = 0.06). Tumor MVD in VEGF and radiation-treated
groups decreased to between 15% and 30% of control or radiationtreated groups (p = 0.001) (Fig. 7). There was no significant difference
in MVD between high-dose VEGF Trap–treated with radiation vs. high
dose VEGF Trap alone (p = 0.29). However, there was a significant
difference in MVD between low-dose VEGF Trap-treated with radiation
and low-dose VEGF Trap alone (p = 0.01, Fig. 8).
18-fluorodeoxyglucose–PET imaging of VEGF Trap–treated tumors
Figure 9a illustrates a series of images from a representative, untreated
mouse. Figure 9b represents a series of images from a representative
mouse treated with VEGF Trap dosed at or 10 mg/kg every 3 days
(starting at Day 0) for 3 weeks. Tumor volume (mm3) and days following
start of treatment are indicated. Because of the difficulty in matching
tumor volumes and time after treatment, the percent of metabolically
inactive tumor volume (as measured by FDG uptake) was measured as
a function of tumor volume and averaged over a range of tumor volumes
between 900 and 1,600 mm3. The percent of metabolically inactive
tumor was significantly less in untreated tumors (2.46% ± 0.18%) than
in tumors treated with 10 mg/kg VEGF Trap (8.7 ± 1.26%, p = 0.01) but
not significantly different from tumors treated with 2.5 mg/kg VEGF
Trap (3.36 ± 0.36%, p = 0.13) .

This work demonstrated that VEGF Trap alone is an effective dosedependent inhibitor of tumor growth in U87GBM. These findings
agreed with previous studies of VEGF Trap in other preclinical animal
models demonstrating efficacy in halting angiogenesis and shrinking
tumors30. Because VEGF Trap was very potent by itself and could have
potentially masked any additional benefits of radiation, both low-dose
and high-dose scheduling of the drug were used with radiotherapy.
In all scheduling protocols that were investigated, the combination of
low-dose VEGF Trap with radiation was significantly better than either
treatment modality alone. On the other hand, high-dose VEGF Trap
was significantly better than radiation alone and therefore masked any
additional benefit that may have resulted from combination therapy.
The benefit of combined treatment with low VEGF Trap and radiation
relative to radiation alone was not influenced by scheduling protocol.
This result was in contrast to earlier work demonstrating improved
radiation response when a VEGFR2 blocker, DC101, was given 4 to
6 days before radiotherapy32. This earlier work suggested that tumor
vasculature normalization occurred during pretreatment with the
VEGFR2 blocker, a process in which pruning of immature and inefficient blood vessels occurs leading to improved tumor perfusion and
oxygenation and improved radiation response. The current observations
may reflect the absence of a normalization effect by VEGF Trap on U87
GBM vasculature or a missed window of opportunity for normalization
because of the particular protocols used in this work. Because it is not
known how tumor oxygenation levels may have varied throughout the
course of combined treatment with VEGF Trap and radiation, additional studies are warranted to resolve the issue of normalization.
The observation that scheduling did not have an impact on efficacy of
combined treatment with VEGF Trap and radiation in this study is also
in contrast to recent studies in which VEGF blockade was obtained either
by a VEGF receptor2 tyrosine kinase inhibitor, ZD6474, or indirectly by

Table 4. VEGF Trap sequenced post–fractionated radiation: Summary of tumor growth (Schedule IV)
Treatment

%Δ

(95% CI)

T2x

Control (human FC protein)

31.5

(28–35)

2.5

p values

RT (3 x 5 Gy)

15.0

(13–17)

5.1

0.001 vs. control, 0.460 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)

VEGF Trap (2.5 mg/kg)

16.0

(13–19)

4.7

0.001 vs. control, 0.460 vs. RT alone

VEGF Trap (10 mg/kg)

8.0

(5–10)

9.2

0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)

VEGF Trap (low) + RT

10.0

(7–12)

7.4

0.011 vs. RT, 0.001 vs. VEGF Trap (low)

VEGF Trap (high) + RT

5.5

(3–8)

12.8

0.001 vs. RT, 0.187 vs. VEGF Trap (high), 0.013 vs. VEGF Trap (low) + RT

Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
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Radiotherapy

This work is encouraging in that it demonstrates for the first time a
benefit in combining VEGF Trap with ionizing radiation in a highly resistant GBM tumor model. VEGF Trap is a unique human fusion protein
with very potent binding affinity for VEGF A isoforms as well as placental
growth factor (PIGF) and is currently in clinical trials. Its affinity for
VEGF is potentially 100- to 1,000-fold higher than existing VEGF monoclonal antibodies such as bevacizumab34. This high-affinity blockade of
VEGF differentiates VEGF Trap from other anti-VEGF strategies and
therefore gives this drug the potential to enhance combination modality
treatment with lower dosing.

Average Microvessel Density
(% Area Blood Vessels)

10
8
6
4
2
0
Control

RT

2.5mg/kg 10mg/kg 2.5 mg/kg 10 mg/kg
+ RT
+ RT

Treatment
Figure 7. Effect of vascular endothelial growth factor (VEGF) Trap
and radiation (RT) (Schedule II) on microvessel density (MVD).
Tumor MVD in VEGF Trap–treated tumors was decreased to
between 43% and 57% of control or RT-treated tumors (p = 0.06).
Tumor MVD in VEGF Trap and RT-treated groups decreased to
between 15% and 30% of control or RT-treated groups (p = 0.001).
There was no significant difference in MVD between VEGF Trap–
treated (high dose) + radiation vs. VEGF Trap (high dose) alone
(p = 0.29). However, there was a significant difference in MVD
between VEGF Trap (low dose) + radiation and VEGF Trap (low
dose) alone (p = 0.01).
HIF-1 alpha blockade of VEGF secretion. In both these studies, optimal
antitumor efficacy was obtained when VEGF blockers were sequenced
following radiation2, 33. These studies suggested that prolonged suppression of radiation-induced angiogenesis account for enhanced efficacy
of combined treatments with angiogenesis blockade and radiation.
However, it is not clearly understood why there is a difference in the
impact of scheduling among these agents.

Control

VEGFT L

Mechanisms of enhanced U87 tumor control by combined therapy with
VEGF Trap and radiation most likely include inhibition of radiationinduced angiogenesis by VEGF Trap sequestration of circulating VEGF
in the bloodstream and in the extracellular tumor space resulting from
radiation-induced secretion. Indeed, in this study, a radiation-dosedependent increase in VEGF secretion by U87 glioblastoma cells was
observed and excess VEGF was bound in the presence of VEGF Trap. In
addition, immunohistochemical findings indicated a reduction in MVD
3 weeks following treatment with VEGF Trap and radiation. Inhibition
of radiation-induced angiogenesis was also observed indirectly through
FDG–PET imaging, which revealed an increase in metabolically inactive tumor tissue after VEGF Trap treatment, possibly arising from the
induction of tumor necrosis or apoptosis in the presence of angiogenesis
inhibition. It is also of interest that in this study, a brief period of fraction-

A

B

VEGFT H
*Volume (mm3) / (days
post-treatment)

Figure 9. 18-fluorodeoxyglucose (FDG)–PET imaging of human

Radiation

VEGFT L + R

VEGFT H + R

Figure 8. Platelet– endothelial cell adhesion molecule 1 (PECAM1) staining in subcutaneous U87 glioblastoma xenografts treated
with vascular endothelial growth factor (VEGF) Trap with and
without radiation therapy (Schedule II). Lower microvessel density
(MVD) and altered vessel morphology were observed in treated
tumors. (VEGFT L = VEGF Trap low dose; VEGFT H = VEGF Trap
high dose; R = radiation) Original magnification: X 100.

U87 glioblastoma xenografts in nude mice. (a) A series of typical
images from an untreated mouse. (b) A series of images from a
mouse treated with vascular endothelial growth factor (VEGF)
Trap dosed at 10 mg/kg every 3 days (starting at Day 0) for 3 weeks.
Tumor volume (mm3) and days following start of treatment are
indicated. Imaging was performed as described in Methods and
Materials. The percent of metabolically inactive tumor (as measured
by FDG uptake) was significantly less in untreated tumors than in
tumors treated with 10 mg/kg VEGF Trap.
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ated radiotherapy with VEGF Trap resulted in tumor growth retardation
but not remission. The lack of remission is probably related to continued
production of VEGF after removal of drug and radiation and points to
the need for chronic therapy with VEGF Trap, which is in agreement with
what has been observed for the transient effects of other antiangiogenic
agents on tumor control23, 35.
In conclusion, these studies demonstrate that the combination of lowdose VEGF Trap and radiation is clearly better than radiation alone in
a U87 subcutaneous xenograft model. Although high doses of VEGF
Trap alone are highly efficacious, it is unclear whether such high doses
can be used clinically without incurring normal tissue toxicities. Thus,
information on lower doses of VEGF Trap and ionizing radiation are of
clinical relevance.
It is understood that the SC xenograft model used in this study has
shortcomings in that ectopic tumors implanted SC in the hind limb of
animals do not duplicate the vascular microenvironment of orthotopic
brain implants36. However, the use of hind limb injection is the standard
approach for xenograft studies with radiation. In addition, human xenografts in immunocompromised nude mice, whether they be ectopic or
orthotopic, both have deficiencies in that they can only approximate the
human patient situation and seldom reflect accurately the glioblastoma
multiforme histopathology seen in patients. This study is encouraging in
that it demonstrates for the first time a benefit in combining VEGF Trap
with ionizing radiation and warrants further investigations both preclinically and clinically.
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Hpf, hours post fertilization; Kd, knock down; IR, ionizing radiation
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The p53 family of proteins contains two members that have been implicated in sensitization of cells
and organisms to genotoxic stress, i.e., p53 itself and p73. In vitro, lack of either p53 or p73 can protect certain cell types in the adult organism against death upon exposure to DNA damaging agents.
The present study was designed to assess the relative contribution of p53 to radiation resistance of
an emerging vertebrate model organism, i.e., zebrafish embryos. Consistent with previous reports,
suppressing p53 protein expression using antisense morpholino oligonucleotides (MOs) increased
survival and reduced gross morphological alterations in zebrafish embryos exposed to ionizing
radiation. By contrast, a pharmacological inhibitor of p53 function [Pifithrin-α (PFTα)] caused
developmental abnormalities affecting the head, brain, eyes and kidney function and did not protect against lethal effects of ionizing radiation when administered at 3 hours post fertilization (hpf).
The phenotypic abnormalities associated with PFTα treatment were similar to those caused by
antisense MO knock down (kd) used to reduce p73 expression. PFTα also inhibited p73-dependent
transcription of a reporter gene construct containing canonical p53-responsive promoter sequences.
Notably, when administered at later stages of development (23 hpf), PFTα did not cause overt developmental defects but exerted radioprotective effects in zebrafish embryos. In summary, this study
highlights off-target effects of the pharmacological p53 inhibitor PFTα related to inhibition of p73
function and essential roles of p73 at early but not later stages of zebrafish development.

Introduction
The genotoxic stress response is one of the most widely studied phenomena in biology and the
efforts of many groups have provided a detailed understanding of the molecular determinants of
this homeostatic mechanism (reviewed in refs. 1–3). Yet, the current understanding of the effects of
genotoxic stress on whole organisms is curtailed by the fact that many of the mechanistic insights are
based on experiments with cultured cells. These shortcomings are compounded by pitfalls associated
with the preferential use of immortalized or transformed cells.4 In recognition of these problems,
many groups have resorted to studying the DNA damage response in experimental animals, particularly genetically engineered mice. These efforts have contributed considerably to the understanding
of molecular determinants of the in vivo genotoxic stress response including Ku,5,6 DNA-PK,7 DNA
ligase IV,8 ATM,9 ATR,10 Chk111 and Chk2.12 In addition, these studies confirmed a central role of the
tumor suppressor p53 in the genotoxic stress response (reviewed in refs. 13 and 14).
The present study was undertaken to explore molecular determinants of the genotoxic stress
response in an emerging animal model system, i.e., zebrafish embryos. Zebrafish represents a
vertebrate species with many similarities to mammals. Yet, they breed prolifically and are amenable to large-scale phenotypic screening facilitated by the fact that they are transparent during
organogenesis. Importantly, ‘knockdown’ strategies using antisense MOs have been developed in

this species to investigate protein function in
the in vivo context. Zebrafish are attractive
not only to model human diseases but also as
tools in drug discovery.15 We have previously
reported that zebrafish embryos provide a
rapid, facile system to identify pharmacological modifiers of the radiation response.16 Here,
we extend these studies to assess the contribution of endogenous modifiers of the radiation
response to radiation-induced morbidity and
mortality by focusing on pharmacological and
genetic inhibition of p53 function.

Results and Discussion
Time- and dose-dependent effects of ionizing radiation on zebrafish embryo survival.
Previously, we observed that radiation sensitivity of zebrafish embryos was different at
distinct developmental stages and progressively decreased between 2 to 8 hours post
fertilization (hpf ).16 Here, we extend this earlier
study by assessing embryo survival after exposure to increasing radiation doses up to 72 h
after radiation. These experiments confirmed
progressive radioresistance at successive stages
of development (not shown). To determine
the consequences of inhibiting translation of
specific gene products by antisense MO kd for
radiation resistance of the developing embryo
we performed all subsequent experiments in
embryos which were irradiated at 24 hpf. This
was based on the consideration that, at this time
point, target protein expression is sufficiently
suppressed by antisense MO kd and remains
low for extended time periods up to 4 days post
fertilization (dpf ).17 Dose-dependent survival
upon radiation exposure at 24 hpf revealed
100% lethality scored at 6–7 dpf (40 Gy) with
an LD50 of 20 Gy.18 To monitor the effects of
p53 expression on radiation sensitivity as it
relates to both, mortality and tissue-specific
effects, we thus performed experiments at 20
or 40 Gy.
Reduced p53 expression is associated
with radioprotection of zebrafish embryos.
Zebrafish embryos harboring homozygous
missense p53 mutations exhibit increased
resistance to the deleterious effects of ionizing
radiation.19 We determined whether suppressing
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Effects of the pharmacological p53 inhibitor PFTα on development
and radiation sensitivity of zebrafish embryos. PFTα was originally
identified as an inhibitor of p53-dependent transcription22 and it reduced
the sensitivity of mice to the deleterious effects of ionizing radiation.23
Based on these previous studies we tested whether PFTα also protected
zebrafish embryos against radiation-associated toxicity (Fig. 2A). Unexpectedly, when added to zebrafish embryos at 3 hpf (sphere stage), PFTα
(2 μM) caused malformations affecting the head region and led to the
development of massive edema affecting the whole body of treated fish
at later stages of development (Fig. 2B and Table 1). Furthermore, it has
been described earlier that PFTα treatment also reduces overall survival
of zebrafish embryos.21 These results together raised the question whether
PFTα exerted effects on molecular targets other than p53, which confound
potential radioprotective properties of PFTα in the zebrafish embryo.
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Figure 1. Antisense morpholino oligonucleotides (MOs) targeted to
p53 increase embryo survival and reduce ionizing radiation-induced
apoptosis evident in the head and trunk regions. (A) Embryo survival.
Triplicate dishes of 60 embryos each were scored for live embryos daily
after 20 Gy IR administered at 24 hpf. Necrotic dissolution or absent
heartbeat were considered criteria for embryo death. (B) Restoration of
IR sensitivity by restoring p53 expression using G-capped zebrafish p53
mRNA. Triplicate dishes of 60 embryos each were scored as described
above at 6 dpf (5 days post IR). Asterix (*) p53kd vs p53kd-p53 mRNA; p
< 0.05; t-test, one-tailed). (C) Attenuation of IR-induced apoptosis by p53
kd as assessed by quantification of acridine orange (AO) staining at 30
hpf. Sixty embryos per condition (Control, phenol red control; p53 mm,
mismatch antisense MO; p53 kd, p53 antisense MO; p53 kd-p53mRNA,
rescue coinjection with p53 antisense MO and p53 G-capped mRNA)
were pooled and stained with AO as described in Materials and Methods.
Pooled embryos were transferred to 95% ethanol for 15 minutes to
extract the AO for fluorescence determination. Triplicate measurements
for each condition were performed on a FL600 microplate fluorescence
reader (Bio-Tek) and normalized to control background fluorescence
and reported as relative fluorescence units (RFU).
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p53 expression by antisense MOs20 similarly induced a radioresistant
phenotype. We observed that p53-targeted MO kd markedly improved
survival of zebrafish embryos irradiated with 20 Gy at 24 hpf (Fig. 1A)
whereas coinjection of capped p53 mRNA restored radiation sensitivity
(Fig. 1B). Similarly, p53-targeted MO kd markedly reduced the incidence
and severity of radiation-induced morphological defects, notably defects
in midline development that manifest as dorsal curvature of the body
axis (Fig. S1). These results were similar to results by Duffy and Wickstrom published during preparation of this manuscript.21 In addition,
p53-targeted MO kd markedly reduced the extent of radiation-induced
apoptosis as determined by acridine orange staining (Fig. 1C).

PFTα treatment mimics morphological effects associated with knockdown of p73 expression in zebrafish embryos. P73 is a likely candidate
for off-target effects of PFTα because p73 binds to and transactivates
p53 responsive promoters.24 Thus, we determined whether suppression
of p73 expression by antisense MO kd caused developmental defects
similar to those observed in PFTα treated embryos. A previous report
showed that targeting p73 adversely affected development of the head
region, i.e., the olfactory system, the telencephalon and the pharyngeal
arches of zebrafish embryos.25 In addition, p73 is expressed at high levels
in the developing kidneys.26 We observed that p73-targeted antisense
MO-mediated kd induced head region abnormalities (Fig. 3A) and led
to liquid accumulation affecting the whole body of treated fish (Fig. 4
and Table 2). These changes were very similar to the morphological
alterations observed in PFTα-treated fish (Fig. 2B). Furthermore, alcian
blue staining revealed severe disturbances of branchial arch development
associated with either PFTα treatment or p73-targeted antisense MO kd
(Fig. 3B). These defects were, at least partially, reversed by coinjection
of G-capped p73 mRNA and not observed in embryos injected with p73
mismatched antisense MO.
Impaired kidney function in zebrafish treated with PFTα and p73
morpholinos. This is the first report of edema formation upon treatment
of developing embryos with p73-targeted antisense MO kd. We hypothesized that this phenotype was due to impaired renal clearance consistent
with high-level expression of p73 in the developing kidneys.26 To address
this issue we used a renal function assay, which measures retention of a
fluorescent dextran within 24 h after injection into the cardiac venoussinus.27 As compared to control fish receiving mismatch antisense MO,
the p73-targeted antisense MO kd caused markedly reduced clearance
of this contrast agent (Fig. 5). In contrast, control p53-specific antisense
MO kd did not affect dextran retention. Importantly, PFTα treatment not
only led to liquid accumulation in fish embryos in a manner similar to
p73-targeted antisense MO kd but it also increased dextran retention in
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Figure 2. PFT-α (2 μM) administered to zebrafish embryos at 3 hpf does not protect against the lethal effects of IR and is associated with developmental
abnormalities. (A) Embryo survival scored as described in Figure 1A. (B) Embryo morphology in the different experimental conditions as indicated.
Representative embryos were digitally photographed at 4x magnification and processed using NIH ImageJ software.

Table 1.
Incidence of whole body edema caused by PFTα treatment
Normal

Edema

Total

Edema (%)

Control

77

0

77

0

PFTα (2μM)

18

29

47

62

Triplicate dishes (30 embryos each per condition) of live embryos at 7 dpf were scored for edema as shown
in Figure 2B and results expressed as percent edema.

a similar fashion. In these experiments, kidney function was tested at 3
dpf and prior to the development of edema to avoid confounding effects
of the liquid accumulation on embryonal kidney function.
An alternative explanation for the profound edema in zebrafish embryos
following IR exposure is that this effect was caused by reduced cardiac
function.28 To investigate this possibility, we performed time-lapse
microscopy of cardiac contractility in control and irradiated fish embryos.
Quantitative analysis of the images revealed only marginal effects of
either PFTα treatment or p73-specific antisense MO kd on heart rate
and blood flow (not shown). Collectively, these results suggest that the
edema observed in PFTα and p73 antisense MO kd zebrafish embryos is
due primarily to compromised renal function.
PFTα inhibits p73-dependent transactivation of a p53-responsive promoter construct. The striking similarities in developmental
abnormalities caused by either PFTα treatment of suppression of p73
expression raised the question whether PFTα targeted not only p53dependent but also p73-dependent transcription. Using a p53 responsive
reporter gene construct and zebrafish p53 and p73 expression plasmids
cotransfected into Saos-2 cells we observed that PFTα not only inhibited
p53-dependent transcription but also p73-dependent transcription in a
dose-dependent manner (Fig. 6).
It should be noted that administration of PFTα shortly before radiation
(i.e., at 23 hpf ) did not cause developmental abnormalities either of the
craniofacial region or systemic edema and provided a measure of protection against radiation similar to that observed in p53 antisense MO kd
fish (Fig. S1). This result indicates that p73 serves essential functions
during the first 24 h of zebrafish development but is less relevant at later

developmental stages and, presumably, in the adult organism. This circumstance also explains why inhibition of p73 function by PFTα has not
been obvious in previous in vitro or in vivo studies in adult mice.
In summary, this report demonstrates the utility of the zebrafish
model system in characterizing drug effects and highlights previously
unrecognized effects of the p53 inhibitor PFTα related to inhibition
of p73 function. Lack of either p53 or p73 function is associated with
chemoresistance of transformed cells.29 Furthermore, p73 is induced
after DNA damage by the checkpoint kinases Chk1 and Chk2.30 Based
on these results, p73 has been considered as the “assistant” guardian
of the genome that acts in concert with p53 to limit propagation of
cells with damaged DNA.31 Since we observed that PFTα inhibits not
only p53-dependent but also p73-dependent transcription the overall
radioprotective effect of PFTα as observed in mice may, thus, be due to
inhibition of p53 and p73 function. Indeed, short-term pharmacological
inhibition of both, p53 and p73 may be superior to inhibition of p53
alone to protect normal adult cells and tissues against deleterious effects
of radiation.

Materials and Methods
Embryo harvesting and maintenance. Zebrafish husbandry, embryo
collection, dechorionation and embryo maintenance were performed
according to accepted standard operating procedures32 and with approval
by the Institutional Animal Care and Use Committee at Thomas Jefferson University. Zebrafish were maintained in the Zebrafish Core Facility
of the Kimmel Cancer Center at Thomas Jefferson University at 28.5°C
on a 14-h light/10-h dark cycle.
Zebrafish morphology by visual analysis. For visual analysis, zebrafish
embryos were anesthetized with 0.003% tricaine, placed on 3% methylcellulose on a glass depression slide and analyzed using an Olympus
BX51 microscope (Olympus, Melville, NY) at 4x magnification. Images
were recorded using a SPOT camera and SPOT Advanced software
(SPOT Diagnostic Instruments, Sterling Heights, MI).
Targeted knock down of gene expression. Antisense MO sequences
targeting p53, p73 and controls (5 base mismatches; p53 mm, p73 mm)
were as described.20,25 For microinjection, a 0.5 mM oligonucleotide solution was prepared in 10x phosphate-buffered saline solution, diluted 9:1
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Figure 4. Phenotypic abnormalities associated with PFT-α treatment
are similar to those caused by MO-mediated p73 kd. PFT-α was administered at 3 hpf. Embryo morphology and rescue by G-capped mRNA.
Representative embryos were digitally photographed at 4x magnification
and processed using NIH ImageJ software.
Table 2. Incidence of whole body edema caused by p73kd
Normal

B
Control

PFT-α 2 μM

Edema

Total

Edema (%)

Control

219

1

220

0

p73 MO

121

126

247

51

p73 mm

64

4

68

6

p73 MO/mRNA

151

37

188

20

Live embryos at 7 dpf were scored for edema as described in Figure 4 and results expressed as
percent edema.

p53 kd

p53 kd/p73 kd

p73 kd

p73 kd/
p73 mRNA

p73 mm

Figure 3. PFT-α treatment (2 μM at 3 hpf) affects cranio-facial development reducing brain, eye and auditory organ size. (A) Embryo head
morphology at 6 dpf. Representative embryos were digitally photographed at 10x magnification and processed using NIH ImageJ software
(a) snout, (b) eyes, (c) auditory cup. (B) Alcian blue staining (described
in Materials and Methods) of cartilage shows markedly abnormal
cranio-facial development associated with PFT-α treatment and with
p73 antisense MO kd.
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(v:v) with Phenol Red dye, and ~1 nL injected into 1–4 cell embryos
using a nitrogen gas pressure injector (Harvard Apparatus, Cambridge,
MA). To account for non-specific effects of MO oligonucleotides, rescue
experiments were carried out by coinjection of MOs with G-capped
mRNA of the respective target gene. To this end, triplicate dishes of 60
embryos were injected with 4.5–7.5 pg of mRNA generated by cloning the zebrafish p53 cDNA or p73 cDNA into the pCS2+ vector and
producing mRNA with the mMessage-mMachine SP6 kit (Ambion,
Austin, TX).
Radiation exposure and PFTα protection. Triplicate dishes (60 embryos
each) were irradiated at 24 hpf (20 Gy) using 250 kVp X-rays (PanTak, East
Haven, CT) at 50 cm source-to-skin with a 2-mm aluminum filter. Dosimetric calibration was performed before each experiment using a thimble
ionization chamber (Victoreen; Elimpex-Medizintechnik, Moedling, Austria) with daily temperature and pressure correction. Pifithrin-α (EMD
Biosciences, San Diego, CA) was solubilized in DMSO and diluted with
embryo media. PFTα was applied 30 minutes prior to IR.
Kidney function assay. A 1% solution of rhodamine-labeled dextran (10
kDa; Molecular Probes) in PBS was injected (3 dpf ) using glass micropipets into the cardiac venous sinus of embryos immobilized in 3% methyl
cellulose. Prior to injection, embryos were anesthetized using a 0.003%
tricaine solution in egg water.33 After injection, the embryos were washed
in egg water for 10 minutes and placed back into 3% methylcellulose
on a glass depression slide. Fluorescence was quantitated using ImageJ
software (NIH, USA). The analysis was repeated at 24 h after dextran
injection. Percent dextran retention at 24 h was calculated using the formula: (intensity 24 h/intensity 0 h) X 100.
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Figure 5. Reduced kidney function by either PFT-α treatment or p73 kd as determined by increased fluorescent dextran retention. (A) Rhodamine labeled
dextran staining is described in Materials and Methods. Representative images are shown at 0 and 24 h. (B) Quantification of dextran label retention at 24 h
after dye injection. Three embryos per condition were quantified for dye retention using NIH imageJ software.
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Figure 6. PFT-α inhibits p73-dependent transcription of a reporter gene construct. Triplicate wells (48-well plate) were transfected with pCMV- gal and
p53 pr-RLuc plasmids together with either a pCMV-zp53 (A) or a pCMV-zp73 plasmid. (B) Renilla luciferase activity was assayed 48 h post transfection
and normalized to -gal activity as described in the Materials and Methods. Cells were treated with PFT-α 15 minutes before transfection. Asterix (*) p < 0.5
(tukey test); **p < 0.01(tukey test).
Alcian blue staining. Alcian blue staining was performed according to
Neuhauss et al.,34 with the following modifications. Embryos (4 dpf )
were fixed overnight in Davidson’s Solution (Electron Microscopy Sciences, Hatfield, PA) and rinsed 3x for 10 min in PBS and transferred to
neutral buffered formalin for 2 days at 4°C. The embryos were then transferred into distilled water and stored at 4°C. For Alcian blue staining, the
samples were washed in PBT (0.1% Tween-20 in PBS) and transferred
into 30% H2O2 (Sigma, St. Louis, MO) and bleached for 4–5 hours or
until eyes became translucent. After bleaching, the embryos were rinsed
in PBS for 15 min and transferred to filtered Alcian Blue solution (1%
conc HCl, 70% Ethanol, 0.1% Tween-20) and stained overnight. The
stain was cleared with acidic ethanol (5% conc HCl, 70% ethanol).

Acridine orange staining. Zebrafish embryos were dechorionated and
placed in 50 μg/ml of acridine orange (Sigma) in fish water. After 30 min
of staining, embryos were washed 3x for 10 min in PBS. Pooled embryos
were transferred to 95% ethanol for 15 minutes to extract the AO for
fluorescence determination. Triplicate measurements for each condition
were performed on a FL600 microplate fluorescence reader (Bio-Tek)
and normalized to control background fluorescence and reported as relative fluorescence units (RFU).
In vitro reporter gene assays. Saos-2 cells (ATCC Rockville, MD) were
cultured in DMEM supplemented with 10% fetal calf serum. Cells were
cultured to 60–70% confluence and transferred to 48-well plates at a
density of 2.6 x 104 cells/well. Cells were transfected with three plasmids
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using Fugene (Roche). The p53 reporter plasmid was constructed by
inserting the synthetic p53-responsive promoter containing 14 tandem
p53 enhancer elements and a TATA-box (Pathdetect p53-cis reporter,
Stratagene) into the pRLnull plasmid (Promega) to drive the Renilla
luciferase gene (p53 pr-RLuc). For normalization, a B-galactosidase
reporter plasmid was used (pCMV-Bgal;35). Renilla luciferase activity was
measured 48 hrs after transfection using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI) and B-gal activity was measured
using the Beta-Glo Reporter Assay System (Promega, Madison, WI)
according to the manufacturer’s specifications. Cells were treated
with PFTα 15 minutes before transfection. Chemiluminescence was
measured using a Veritas Microplate luminometer (Turner Biosystems,
Sunnyvale, CA).
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Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers.
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Purpose
Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology Group
(RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The locoregional control
and survival rates were similar among the various dose levels.We investigated the effect of the gross
tumor volume (GTV) on the outcome.
Methods and Materials
The GTV was defined as the sum of the volumes of the primary tumor and involved lymph nodes.
The tumor response, median survival time (MST), and progression-free survival (PFS) were analyzed
separately for smaller (≤45 cm3) vs. larger (>45 cm3) tumors.
Results
The distribution of the GTV was as follows: ≤45 cm3 in 79 (49%) and >45 cm3 in 82 (51%) of 161
patients. The median GTV was 47.3 cm3. N0 status and female gender were associated with better
tumor responses. Patients with smaller (≤45 cm3) tumors achieved a longer MST and better PFS
than did patients with larger (>45 cm3) tumors (29.7 vs. 13.3 months, p < 0.0001; and 15.8 vs. 8.3
months, p < 0.0001, respectively). Increasing the radiation dose had no effect on the MST or PFS.
On multivariate analysis, only a smaller GTV was a significant prognostic factor for improved MST
and PFS (hazard ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a
continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p < 0.0001;
and HR, 1.39, p < 0.0001, respectively).
Conclusions
Radiation dose escalation up to 90.3 Gy did not result in improved MST or PFS. The tumor responses
were greater in node-negative patients and women. An increasing GTV was strongly associated
with decreased MST and PFS. Future radiotherapy trials patients might need to use stratification by
tumor volume. ©2008 Elsevier Inc.
Key Words: Tumor volume, Lung cancer, Radiotherapy dose escalation.

Introduction
The current American Joint Committee on Cancer staging system for the primary tumor in lung
cancer is based mostly on the tumor extent and involvement of the neighboring structures (e.g.,
pleura, chest wall, mediastinum, bone, esophagus, and proximal airways) rather than on tumor
size or volume. A notable exception is Stage T1, in which a tumor surrounded completely by lung
parenchyma cannot exceed 3 cm in the largest dimension. However, a Stage T2 tumor can measure
1.5 cm or 8 cm, as long as it invades the visceral pleura only, with sparing of the other structures.

Evidence has been accumulating1–11 that an
increasing tumor volume has a significant
effect on patient outcome, possibly even
overriding the T stage assignment. Other factors
influencing the American Joint Committee on
Cancer stage assignment are nodal involvement
and the presence of distant metastases.
In a recently published Radiation Therapy
Oncology Group (RTOG) Phase I-II study12
of radiation dose escalation for patients
with inoperable non–small cell-lung cancer
(NSCLC), the observed locoregional control
rates and survival rates were similar between
treatment groups, receiving escalated radiation
doses (from 70.9 Gy to 90.3 Gy, depending on
the volume of lung receiving ≥20 Gy [V20]).
A reasonable initial hypothesis would be,
however, to expect that smaller tumors should
demonstrate improved local control with greater
radiation doses compared with larger tumors.
To investigate this hypothesis, we undertook a
retrospective analysis of data from the RTOG
93-11 clinical trial in an attempt to demonstrate
any benefit of radiation dose escalation for
patients with smaller tumors and to determine
any relationship between the initial tumor
volume and patient outcome.

Methods And Materials
Patient population
The RTOG 93-11 study was a Phase I-II
radiation dose escalation trial for patients with
inoperable Stage I-III NSCLC treated with
three-dimensional (3D) radiotherapy alone,
without concurrent chemotherapy, although
induction chemotherapy was allowed.
The primary objective of the study was to
determine the treatment-related morbidity and
to determine the maximal tolerated radiation
dose. The secondary objectives were to
determine the local control and overall survival
(OS) rates. The patient population consisted of
subjects with NSCLC (inoperable Stage I, II,
and IIIA and Stage IIIB; supraclavicular nodes
involvement was not allowed; Table 1). Patients
were treated according to the volumetric
treatment planning computed tomography
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findings and the gross tumor volume (GTV) included the primary
tumor and any enlarged regional lymph nodes (>1 cm) with a minimal
3D margin of 1 cm. Noninvolved nodal areas were not irradiated, and
no special effort was made to account for the respiratory motion, apart
for assessing motion with fluoroscopy. Patients were placed into doseescalation groups according to the V20 value in their radiotherapy (RT)
plan, predicting the likelihood of treatment-related pneumonitis13.
Patients with a V20 of <25% were assigned to Group 1 and received
an escalated dose to 70.9, 77.4, 83.8, or 90.3 Gy. Patients with a V20 of
26–35% were assigned to Group 2 and received an escalated dose to 70.9,
77.4, or 83.8 Gy. Patients with a V20 of >35% were assigned to Group 3
and received an escalating dose to 64.5, 70.9, or 77.4 Gy. All fraction sizes
were 2.15 Gy. The study accrued patients only to Groups 1 and 2. Group
3 enrollment was stopped because of poor accrual.

the purpose of this investigation, tumor response, OS, and PFS were
analyzed separately for the smaller tumors (≤45 cm3) vs. larger tumors
(>45 cm3), first among all patients and, later, within each radiation dose
level. GTV was also analyzed as a continuous variable. The association
of response (CR/PR vs. stable/progressive disease) and the GTV
categorized by cutpoint was tested by Fisher’s exact test. OS and PFS were
estimated by the Kaplan-Meier method and tested using the log–rank
test statistic. Univariate and multivariate analyses of OS and PFS with the
GTV and other prognostic factors (age [<60 vs. ≥60], gender, Karnofsky
performance status [90–100 vs. 70–80], histologic type [nonsquamous
vs. squamous], stage [I-II vs. IIIA-IIIB], previous chemotherapy [yes vs.
no], and maximal radiation dose to the lung) were done using the Cox
proportional hazards model. Multivariate modeling used the stepwise
selection method. When analyzed as a continuous variable, GTV was
transformed using a log10 transformation to ensure normality. Patients
with unknown tumor volumes were excluded from this analysis.

Table 1. Patient characteristics
Characteristic

Group 1 (n = 127)

Group 2 (n = 48)

Age (y)
<60
≥60

18 (14)
109 (86)

5 (10)
43 (90)

Gender (n)
Male
Female

72 (57)
55 (43)

22 (46)
26 (54)

KPS (n)
70–80
90–100

85 (67)
42 (28)

30 (63)
18 (37)

Histologic type (n)
Squamous cell carcinoma
Adenocarcinoma
Other

51 (40)
42 (33)
34 (21)

21 (44)
17 (35)
10 (21)

N stage (n)
N0
N1
N2
N3

83 (65)
10 (8)
32 (25)
2 (1)

17 (35)
6 (13)
22 (46)
3 (6)

Abbreviation: KPS = Karnofsky performance status.
Data in parentheses are percentages.

Evaluation of local control, OS, and progression-free survival
A chest X-ray was obtained 4 weeks after RT completion. Computed
tomography scans of the chest were obtained at 6 and 12 months and
repeated yearly thereafter. Local control (complete response [CR] or
partial response [PR] vs. stable or progressive disease) was reported by
the enrolling institutions. No central review of the follow-up computed
tomography scans was performed. OS and progression-free survival
(PFS) were reported as measured from the date of registration in
the study.
Statistical analysis
The GTV was defined as the sum of the volumes of the primary tumor
and involved lymph nodes. In the 3D plans, the primary tumor volume
and the involved nodal volume were outlined as one structure; no data
are available in the RTOG electronic database to allow for separation of
those two volumes. Therefore, in an attempt to at least partially correct
this deficiency, nodal status (N0 vs. N1 or N2 or N3) was analyzed as
one of the variables. This allowed for the separation of the effect of
the tumor GTV vs. nodal GTV (at least for Stage I, or N0, patients).
OS was defined as death from any cause; an event for PFS was local or
regional progression, distant metastases, or death from any cause. For
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Results
Patient characteristics
A total of 176 patients were included in the original report of the study12.
Of the 176 patients, 161 had available data on GTV and tumor response
and were the subject of this secondary analysis. The patient characteristics
are presented in Table 1. Overall, most patients were older (>60 years)
with a Karnofsky performance status between 70 and 80. The patients in
this analysis were approximately equally split between men and women
and those in Group 1 were more likely to have node-negative disease
than were those in Group 2. The distribution of the American Joint
Committee on Cancer stage was Stage I in 67, Stage II in 12, and Stage
III in 48 patients in Group 1 and Stage I in 10, Stage II in 3, and Stage III
in 35 patients in Group 2.
Tumor response, OS, and PFS
The GTV was ≤45 cm3 in 79 (49%) and >45 cm3, 82 (51%) of 161 patients
(median, 47.3; range, 1.9–1,039.9 cm3); 14 patients had an unknown
GTV. The tumor response rate (CR/PR) was better for smaller tumors
(≤45 cm3) than for larger tumors (>45 cm3; 87% vs. 76%, respectively),
as was stable/progressive disease (13% vs. 24%, respectively; p =
0.0691, Fisher’s exact test). Results using a cutoff point of 30 cm3 did
not better distinguish between those patients with a tumor response
and those with stable or progressive disease than using a cutoff point
of 45 cm3 (p = 0.0642). A cutoff point of 60 cm3 did not discriminate
between the two groups (p = 0.4139). When the GTV was analyzed as a
continuous variable, on univariate analysis, it was borderline statistically
significantly associated with tumor response (p = 0.0551); however, on
multivariate analysis, N stage (N0 vs. N1-N3) and female gender were
the only significant variables (p = 0.025 and p = 0.02, respectively). This
can be explained by the greater rate of responses (70%) in patients with
N0 disease vs. N1-N3 (30%).
Patients with smaller tumors (≤45 cm3) achieved a longer median survival
than did patients with larger tumors (>45 cm3; 29.7 vs. 13.3 months, p
< 0.0001; Fig. 1), as well as better median PFS (15.8 vs. 8.3 months; p <
0.0001; Fig. 2).
When a different GTV was chosen as a cutoff point (30 cm3 or 60 cm3),
patients with smaller tumors (≤30 cm3 or ≤60 cm3) still achieved better
OS (32.9 vs. 14.6 months for 30 cm3, p = 0.0002; and 26.8 vs. 13.3 months
for 60 cm3, p = 0.0006), as well as better PFS (15.5 vs. 9.0 months for 30
cm3, p = 0.0031; and 14.7 vs. 8.7 months for 60 cm3, p = 0.0023).

Studies

On multivariate analysis of the factors associated with improved OS
and PFS, only a smaller tumor volume was significantly prognostic
for both endpoints (HR, 2.12; p = 0.0002; and HR, 2.0; p = 0.0002,
respectively) when GTV was analyzed as a continuous variable. Age,
gender, performance status, histologic type, N stage (N0 vs. N1-N3),
previous chemotherapy, and maximal radiation dose were not significant
(Tables 2 and 3). The other GTV cutoff points (≤30 cm3, ≤45 cm3, and ≤60
cm3) retained their statistically significant association with improved OS
and PFS on multivariate analysis and again were the only factors in the
multivariate models using a stepwise selection method.
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Figure 2. Five-year progression-free survival rate for patients with gross
tumor volume ≤45 cm3 (solid curve) vs. those with gross tumor volume
>45 cm3 (dotted curve).
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Table 2. Multivariate analysis of overall survival for
different gross tumor volumes used as cutoff point and
as continuous variable
Model*

Comparison

Hazard ratio

95% CI

p†

3

GTV (cm )

<30 vs. ≥30

2.18

1.43–3.32

0.0003

GTV (cm3)

≤45 vs. >45

2.12

1.43–3.13

0.0002

3

12

/

0

0
0

Median

≤ 45 cc 56/79
> 45 cc 74/82

/

29.7 months
13.3 months

// / /
// /

25

/

Median

/
///

Fail/Total

100

0

p<0.0001 (log-rank test)

/

(data not shown). The consistently statistically significant increase in the
relative risk of death for all doses to a GTV >45 cm3 can be attributed to
the strong effect of a larger GTV on OS rather than the radiation dose.
However, the analysis was not powered to detect a dose–tumor volume
interaction, and it could not be ruled out on the basis of this analysis.

% Alive Without Progression

When the effect of GTV was analyzed on univariate analysis, a smaller
GTV was associated with improved OS, with significant hazard ratios
(HRs) for cutoff points of 30 cm3 (HR, 2.15; p = 0.0002); 45 cm3 (HR,
2.14; p < 0.0001); and 60 cm3 (HR, 1.91; p = 0.0008), as well as for GTV
analyzed as a continuous variable (HR, 1.59; p < 0.0001). The other
variables associated with improved OS on univariate analysis were female
gender (p = 0.0407) and nodal status (p = 0.067, borderline significance).
The same factors were significant for PFS on univariate analysis (data
not shown).

24

36

48

Months Since Randomization
Figure 1. Five-year overall survival rate for patients with gross tumor
volume ≤45 cm3 (solid curve) vs. those with gross tumor volume >45
cm3 (dotted curve).
Effect of radiation dose escalation on tumor response, OS, and PFS by
tumor volume
The primary research hypothesis of this study was that higher radiation
doses would lead to increased efficacy in smaller tumors. Table 4 shows
the frequencies and percentages of patients with a CR/PR and stable or
progressive disease for each radiation dose and GTV combination using
the 45 cm3 cutoff point. No evidence was found in these data that the CR/
PR rates increased as the radiation dose increases for the two categories
of GTV (p = 0.2213). Increasing the radiation dose had no effect on OS
or PFS (data not shown for PFS) when examined separately for smaller
vs. larger tumors when the 45-cm3 GTV cutoff point was used (Table
5). The results for the 30-cm3 and 60-cm3 cutoff points were similar

GTV (cm )

≤60 vs. >60

1.87

1.27–2.75

0.0015

GTV‡

Continuous

1.59

1.33–1.91

<0.0001

Abbreviation: CI = confidence interval; GTV = gross tumor volume; KPS = Karnofsky performance status.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs.
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†
Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit
level of 0.10.
‡
GTV transformed using log10 to ensure normalcy.

Discussion
The aim of RTOG 93-11 was to determine the dose-limiting toxicity of
3D RT. The radiation dose was safely escalated to 83.8 Gy for patients
with V20 <25% and to 77.4 Gy for patients with a V20 of 25–36%. The
90.3-Gy dose level was too toxic. The observed locoregional control was
similar among the study arms, without evidence that the higher doses
eliminated or at least lowered the recurrence rates.
Our initial hypothesis was that patients with volumetrically smaller
tumors would have improved survival with radiation dose escalation but
not patients with larger tumors. However, we were not able to demonstrate
that in this secondary analysis of the RTOG 93-11 trial, at least not with
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Table 3. Multivariate analysis of progression-free survival for
different gross tumor volumes used as cutoff point and as
continuous variable

Hazard ratio

Comparison

Hazard ratio

95% CI

p†

3

GTV ≤45 cm , dose 83.8 Gy

17

1.60

0.65–3.93

0.3058

GTV (cm3)

<30 vs. ≥30

1.74

1.20–2.53

0.0039

GTV ≤45 cm3, dose 77.4 Gy

17

1.10

0.43–2.82

0.8432

GTV (cm3)

≤45 vs. >45

2.00

1.40–2.86

0.0002

GTV ≤45 cm3, dose 70.9 Gy

14

1.57

0.63–3.91

0.3301

GTV (cm3)

≤60 vs. >60

1.65

1.16–2.36

0.0056

GTV >45 cm3, dose 90.3 Gy

9

4.20

1.52–11.64

0.0058

GTV‡

Continuous

1.39

1.18–1.64

<0.0001

3

GTV >45 cm , dose 83.8 Gy

13

3.83

1.53–9.60

0.0041

Abbreviations as in Table 2.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs.
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†
Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit
level of 0.10.
‡
GTV was transformed using log10 to ensure normality.

GTV >45 cm3, dose 77.4 Gy

28

2.41

1.06–5.48

0.0361

GTV >45 cm3, dose 70.9 Gy

30

2.61

1.17–5.84

0.0193

the small patient numbers that were available at each radiation dose
level tested. It could be that doses >83.8 Gy in standard fractions are
necessary to eliminate local failure. Additionally, the protracted overall
treatment time of 7–9 weeks might have facilitated tumor repopulation
and therefore attenuated any radiation dose response. Finally, the
PTV margins were tight (1–1.5 cm around the GTV), which might
have increased the likelihood for a marginal miss in mobile tumors,
obliterating any potential benefit of dose escalation.

In the reports of highly hypofractionated (‘‘radioablative’’) RT using
precise localization techniques to account for tumor motion, very high
local control rates have been achieved in medically inoperable patients
with Stage I NSCLC receiving 60 Gy in three fractions of 20 Gy each10
or other hypofractionated regimens11. Such doses have not yet been
tested in Stage III NSCLC and might be too dangerous for large and
central tumors.

A significant interaction between radiation dose and tumor size was
shown in the University of Michigan retrospective analysis5 of 114
patients with medically inoperable Stage I and II NSCLC treated with 3D
conformal RT in a dose-escalation study. Patients treated to a biologically
equivalent dose of ≤79.2 Gy lived longer if their tumors did not exceed
51.8 cm3 in volume. However, patients treated to a biologically equivalent
dose of >79.2 Gy had the same overall survival, irrespective of tumor
volume. With all the limitations of the retrospective study, a hypothesis
has been raised that radiation dose escalation can result in improved
outcome in NSCLC, at least in node-negative, early-stage tumors.

Table 4. Frequency of tumor response subdivided by radiation
dose level and gross tumor volume cutpoint of 45 cm3
Incidence (n)
3

GTV ≤45 cm

CR/PR

SD/PD

p*

Dose 70.9 Gy
Dose 77.4 Gy
Dose 83.8 Gy
Dose 90.3 Gy
Dose 70.9 Gy
Dose 77.4 Gy
Dose 83.8 Gy
Dose 90.3 Gy

13 (93)
14 (82)
15 (88)
23 (88)
21 (70)
19 (68)
12 (92)
8 (89)

1 (7)
3 (18)
2 (12)
3 (12)
9 (3)
9 (32)
1 (8)
1 (11)

0.2736

Abbreviation: CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease;
GTV = gross tumor volume.
Data in parentheses are percentages.
*Fisher’s exact test.
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Model*

95% CI

p†

n

Model*

Such a benefit has been suggested in the Memorial Sloan-Kettering
Cancer Center experience4, with the observation of improved local
control and survival in Stage III NSCLC patients with large (>100 cm3)
tumors treated with radiation doses >64 Gy compared with those who
received lower radiation doses.

32

Table 5. Multivariate analysis of overall survival subdivided by
radiation dose level and gross tumor volume cutpoint of 45 cm3

Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.

We found that the increasing tumor volume, defined as the sum of the
primary tumor volume and the volume of the involved lymph nodes,
was associated with a greater risk of local failure, with significantly better
control achieved with tumors <45 cm3 than with the larger tumors. The
45-cm3 volume corresponds roughly to a spherical tumor diameter of
4.4 cm. It must be remembered that the ‘‘tumor volume’’ in our analysis
denoted a sum of the volume of the primary tumor and the involved
lymph nodes, if any. However, in the multivariate analysis of the tumor
volume studied as a continuous variable, it was only the earlier nodal
stage and female gender, not the tumor volume, that was associated with
better local control. In reality, those two variables (volume and nodal
stage) overlap to a large degree, because Stage I NSCLC is defined as a
node-negative tumor measuring ≤3 cm in the largest dimension. Separate
values for the primary GTV and the nodal GTV were not available in the
RTOG 93-11 study; therefore, we were unable to isolate their respective
influences on outcomes.
Because a rigorous evaluation of locoregional control was not performed
in the RTOG 93-11 trial, local control was not assessed in an actuarial
fashion and the radiographic responses might not reflect the true biologic
tumor elimination; using survival as an endpoint is a more objective
measure of the relevance of tumor volume. A strong association of
increasing tumor volume with worsened survival and PFS was observed
in our analysis, overriding other known prognostic factors for survival,
such as lower disease stage.
Such an association has been previously reported1–9. In 207 patients with
inoperable NSCLC (Stage I-III) treated at the Washington University
with 3D-conformal thoracic RT1, overall survival, cause-specific
survival, and local tumor control were highly correlated with the GTV,
and the GTV (and pathologic findings) were predictive for survival on
multivariate analysis, but overall stage and nodal stage were not. Those
patients with tumor volumes not exceeding 33 cm3 appeared to have the
best outcome.
Local response was evaluated volumetrically on 107 followup thoracic
computed tomography scans of 22 patients (19 with Stage III NSCLC)

Studies

treated with definitive thoracic RT2. A volumeof ≤63cm3 and a diameter of
≤4 cm were significantly associated with improved local control compared
with larger volumes or diameters. In a large series from Wuerzburg6, 784
scans of 136 patients were evaluated volumetrically, and a cutoffpoint of
100 cm3 for tumor volume was a discriminating factor for local control,
but not survival. In that study, the primary tumor volume and nodal
volume were measured separately. The total tumor volume (tumor
plus nodes), as well as primary tumor volume alone, was a significant
prognostic factor for survival in a Japanese group experience7.

3.

Belderbos JS, Heemsbergen WD, DeJaeger K, et al. Final results of a phase I/II dose escalation trial
in non–small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol
Biol Phys 2006;66:126–134.

4.

Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses
of radiation in large-volume Stage III non–small-cell lung cancer. Int J Radiat Oncol Biol Phys
2004;60:741–747.

5.

Zhao L, West B, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross
tumor volume in patients with medically inoperable early-stage non–small-cell lung cancer. Int J
Radiat Oncol Biol Phys 2007;68:103–110.

6.

Willner J, Baier K, Caragiani E, et al. Dose, volume and tumor control prediction in primary radiotherapy of non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:382–389.

Because most of the studies cited in our report included a significant
proportion of patients with nodal involvement (N1-N3), the relative
prognostic value of the ‘‘T’’ tumor volume vs. the ‘‘N’’ nodal volume
needs to be elucidated. One would expect that worse survival and possibly
lower local control would be associated with an increasing nodal volume
rather than the primary tumor volume. However, contradictory data
have been published on this issue. On univariate analysis of the factors
associated with overall survival and failure-free survival in a Phase III radiation dose-escalation trial3, only the increasing GTV (defined as
tumor plus nodes), but not the nodal stage or the overall stage, were
predictive. Similarly, in the Japanese experience7 of 71 patients with
Stage III NSCLC, on univariate analysis, the total tumor volume and the
primary tumor volume were significant and the nodal volume was not.
On multivariate analysis, the total tumor volume and primary tumor
volume were both significant prognostic factors.

7.

Basaki K, Abe Y, Kondo H, et al. Prognostic factors for survival in Stage III non–small-cell lung
cancer treated with definitive radiation therapy: Impact of tumor volume. Int J Radiat Oncol Biol
Phys 2006;64:449–454.

8.

8. Chen M, Jiang GL, Fu XL, et al. Prognostic factors for local control in non-small cell lung cancer
treated with definitive radiation therapy. Am J Clin Oncol 2002;25:76–80.

9.

Werner-Wasik M, Peqignot E, Garofola B, et al. Volume of involved mediastinal lymph nodes
and tumor location are predictive of tumor recurrence: Classification and regression tree (CART)
analysis of patients with Stage III non-small cell lung cancer [Abstract]. Proc ASCO 2003;22:638.

10. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: Results of a phase
I study in medically inoperable Stage I non-small cell lung cancer. Chest 2003;124:1946–1955.
11. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage
I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional
study. Cancer 2004;101:1623–1631.
12. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 93-11:A phase I-II
dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable
non–small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318–328.
13. Graham MV, Purdy JA, Emami B, et al. Clinical dose–volume histogram analysis for pneumonitis
after 3D treatment for non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 1999;45:323–329.

Investigators from Shanghai Medical University8 created a prognostic
index model predicting for local control in patients with NSCLC treated
with RT. Patients with a smaller tumor volume (primary plus nodal),
earlier clinical stage, and treated with higher total irradiation dose with
a shortened overall treatment time had better local control.
In a Classification and Regression Tree analysis of the Thomas Jefferson
University’s 107 patients with Stage III NSCLC (9), an aggregate nodal
volume >12.5 cm3 (sum of volumes of the abnormal hilar and mediastinal
lymph nodes), as well as a central tumor location, but not the primary
tumor volume, were associated with a greater risk of nodal recurrence
and shorter median survival time than a nodal volume of ≤12.5 cm3
(MST 13.9 months vs. 17.1 months, respectively). We are not aware of
other reports that have focused on the prognostic value of the involved
nodal volume.

Conclusions
Our study is one of several publications demonstrating the importance
of tumor volume in patients receiving thoracic RT for NSCLC. It is not
fully clear whether patients with smaller tumors have better outcomes
simply because of the lower number of clonogenic cells or whether
smaller tumors are inherently more biologically favorable; however, the
tumor volume may need to be considered in the staging system for lung
cancer, once user-friendly volume assessment becomes commonplace in
diagnostic studies.
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Purpose
Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck
(SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that
are associated with and might predict severe late toxicity after CCRT.
Methods
Patients were analyzed from a subset of three previously reported RTOG trials of concurrent
chemoradiotherapy for locally advanced SCCHN (RTOG 91-11; 97-03; and 99-14). Severe late
toxicity was defined in this secondary analysis as chronic Grade 3-4 pharyngeal/laryngeal toxicity
(RTOG/EORTC late toxicity scoring system) and/or requirement for a feeding tube ≥2 years after
registration and/or potential treatment-related death (e.g. pneumonia) within 3 years. Case-control
analysis was performed, with a multivariable logistic regression model that included pre-treatment
and treatment potential factors.
Results
A total of 230 patients were evaluable for this analysis, 99 cases (patients with severe late toxicities)
and 131 controls; thus 43% of evaluable patients had a severe late toxicity. On multivariable analysis,
significant variables correlated with the development of severe late toxicity were older age (odds ratio
1.05 per year; p = 0.001); advanced T-stage (odds ratio 3.07; p=0.0036); larynx/hypopharynx primary
site (odds ratio 4.17; p=0.0041); and neck dissection after chemo-RT (odds ratio 2.39; p=0.018).
Conclusions
Severe late toxicity following CCRT is common. Older age, advanced T-stage, and larynx/
hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was
associated with an increased risk of these complications.

mucositis, as summarized in a meta-analysis
by Trotti et al.12. Comprehensive data on late
toxicity from randomized trials of RT +/chemotherapy, however, are sparse. Late toxicity
may include long-term severe dysphagia and
its related effects, including dependence upon
a feeding tube, and have a profound effect on
quality of life. The increased incidence of these
serious, potentially permanent effects after
CCRT is concerning, leading some to question
as to whether chemoradiotherapy is truly a
major improvement in the therapeutic ratio
over radiotherapy alone.13
Starting approximately 15 years ago, the RTOG
conducted a series of prospective clinical trials
using CCRT for locally advanced SCCHN.
General data on efficacy and early and subacute
toxicity have been reported14-16. It is likely,
however, that each individual study is
underpowered for a thorough analysis of late
effects, given sample size and patient attrition
due to mortality and other causes. Consequently,
we performed a secondary analysis of severe late
toxicities from these several trials, specifically
focusing on late toxicities and mortality related
to pharyngolaryngeal dysfunction. An analysis
of potential factors associated with severe late
toxicities was undertaken.

Materials/Methods
As noted above, the three prospective trials
analyzed for this paper have been previously reported. All three studies required an
acceptable performance status (60-100% by
Karnofsky scale); non-metastatic stage III/IV
SCCHN; and good hematologic, renal, hepatic
and cardiovascular function.
Briefly, the three studies are:

Background/Introduction
Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN) treated non-surgically. Meta-analyses
show an improved 5-year survival by approximately 8% when CCRT is compared to radiotherapy
alone1, 2. The advantage of this approach with respect to disease free survival and local-regional
control is greater than 8%3-6, 7-10.
While there are undisputed advantages to CCRT for local-regional control, it increases toxicity
when compared to radiotherapy alone11. Many studies have focused on acute toxicity, particularly
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RTOG 91-1114: A phase III trial of larynxpreserving radiotherapy or chemoradiotherapy
for selected Stage III/IV larynx cancer. For
this analysis, only the concurrent chemoradiotherapy arm was studied; this treatment
in this arm consisted of 70 Gy in conventionally fractionated radiotherapy (XRT) – 2 Gy
once daily – plus three cycles of high dose

RTOG Analysis

cisplatin (100 mg/m2, Weeks 1, 4, and 7). There were 172 patients in
this arm from RTOG 91-11; 88 patients were evaluable for this analysis
of late toxicity.
RTOG 97-0317: A Phase IIR trial of several novel regimens of concurrent chemoradiotherapy for stage III/IV head and neck cancer (excluding
patients who were eligibile for RTOG 91-11). This study included three
arms. Arms 1 and 3 utilized conventionally fractionated XRT as per 9111. Arm 1 chemotherapy was infusional 5-FU and cisplatin, both given
daily during the last two weeks of XRT. Arm 3 chemotherapy was once
weekly cisplatin (20 mg/m2/week) and paclitaxel (30 mg/m2/week).
Arm 2 chemoradiotherapy was modeled upon the prospective phase
II trials performed by the University of Chicago. In Arm 2, although
the total XRT dose remained 70 Gy in 2 Gy fractions, it was delivered
over 13 weeks (week-on, week-off technique); chemotherapy in Arm 2
consisted of concurrent infusional 5-FU and hydroxyurea. There were
231 patients in RTOG 97-03; 102 patients were evaluable for this analysis
of late toxicity.
RTOG 99-1416: A Phase II trial of accelerated radiotherapy with
concurrent chemotherapy for stage III/IV head and neck cancer. This
single arm phase II study consisted of accelerated concomitant boost
radiotherapy to 72 Gy over 6 weeks (as per the concomitant boost arm of
RTOG 90-03), with two cycles of high dose cisplatin (100 mg/m2 weeks 1
and 4). There were 76 patients in RTOG 99-14; 40 patients were evaluable
for this analysis of late toxicity.
All of these studies used conventional radiotherapy techniques, mostly
2-dimensional planning and delivery. No patient received intensity
modulated radiation therapy (IMRT). For this report, a severe late
toxicity was defined as any or all of the following events:

Statistical Analysis
Frequency tables with counts and percentages were used to describe
pretreatment and treatment characteristics for each group. Univariate
and multivariable logistic regression models were used to identify
associations of pretreatment and treatment-related factors with severe
late toxicity. All models were stratified by the 5 treatment arms described
above. The following factors were studied: age (continuous variable);
gender; race (non-black vs. black); KPS (60-80 vs. 90-100); hemoglobin
(continuous variable); weight loss pre-treatment (continuous variable);
T-stage (T1/2 vs. T3/4); N Stage (Nx/0/1 vs. N2 vs. N3); Tumor site
(oral cavity/oropharynx vs. larynx/hypopharynx); radiotherapy dose
received as assessed by late effects BED model (total RT dose multiplied
by (1+ [dose/fraction size] ÷ 3): continuous variable); chemotherapy
dose received (<85% of planned dose vs. > 85% of planned dose); and
post-RT neck dissection (yes vs. no). Variables’ levels were grouped in
order to avoid small cell counts. A stepwise selection procedure was
used to build the multivariable logistic regression model using the above
pretreatment/treatment variables. Entry criterion was set at p < 0.05.
The odds ratios (OR) for each variable in the final model along with
their 95% confidence intervals and p-values are reported. The odds
ratios estimate how much more (less) likely it is to be in the case group
versus the control group among patients with the specific variable level’s
characteristic compared to those patients in the reference level (RL), after
stratifying for treatment arm. The cumulative incidence method was
used to estimate time to severe late toxicity and levels for pre-treatment/
treatment-related variables were compared using the Gray’s test 18, 19.

Table 1. Summary of Patients Excluded from this Analysis

• Grade 3 or greater toxicity (RTOG/EORTC Late Toxicity Criteria)
present > 180 days after the start of XRT and clearly related to
dysfunction of the larynx and/or pharynx (e.g. dysphagia)
• Requirement for a feeding tube/gastrostomy 2 years or longer after the
start of XRT.
• Death without cancer progression and from an uncertain cause in
which laryngeal dysfunction is suspected to be a contributing factor
(e.g. pneumonia) ≤ 3 years from the date of randomization. Patients
who died of unknown causes were included in this category. Review
of these deaths was performed by one of the study authors (MM) in
a manner blinded to any of the patient’s clinical pre-treatment and/or
treatment related characteristics.
Patients who suffered one or more qualifying severe late toxicity events
were only considered to be one “case.”
Patients with severe laryngopharynx dysfunction due to cancer, prior to
the start of treatment, were excluded because of the potential confounding
nature of tumor destruction of critical normal tissues (See Table 1). In
RTOG 91-11, the determination of severe pre-treatment laryngopharynx
dysfunction was based on patients’ on-study data collection form, which
scored airway obstruction and dysphagia on a 4-point scale (none, mild,
moderate, severe/life-threatening); patients with severe/life-threatening
airway obstruction and/or dysphagia based on this form were excluded.
In RTOG 91-11, data on pre-treatment use of feeding tubes were not
collected. In RTOG 97-03 and RTOG 99-14, pre-treatment feeding tube
data were collected, and this was used as the primary means of defining
patients with pre-treatment severe laryngopharynx dysfunction.
Patients with missing/inevaluable data or early death from acute toxicity
were also excluded.

RTOG 91-11 RTOG 97-03 RTOG 99-14 Total
(Original
(Original
(Original
(Original
N=172)
N=231)
N=76)
N=479)
Reason for Exclusion
Severe Pre-treatment
Airway Obstruction

15

—

—

15

Severe Pre-treatment
Dysphagia

5

—

—

5

Pre-treatment Feeding
Tube Dependence

—

62

18

80

Total Excluded due to
Severe pre-treatment
laryngopharynx
dysfunction

20

62

18

100

2

3

1

6

Tumor Recurrence/
death < 3 yrs followup.

52

62

16

130

Missing Data

10

2

1

13

Grand Total Excluded

84

129

36

249

Total Analyzable
for this study

88

102

40

230

Death from Acute
toxicity

Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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Case Group
(n=99)

Control Group
(n=131)

Age
Median
Range
Age ≤ 70
Age > 70

60
33-78
85 (86%)
14 (14%)

56
26-78
118 (90%)
13 (10%)

78 (79%)
21 (21%)

99 (76%)
32 (24%)

Non-Black
Black

90 (91%)
9 ( 9%)

120 (92%)
11 ( 8%)

60-80
90-100

24 (24%)
75 (76%)

20 (15%)
111 (85%)

14.3
7.1-18.2
28 (28%)
71 (72%)

14.2
9.9-18.2
43 (33%)
88 (67%)

Gender
Male
.
Female
Race

KPS

Hemoglobin
Median
Range
Hgb ≤ 13.5 gm/dl
Hgb > 13.5 gm/dl

Weight Loss in Previous 6 months (kg)
Mean
3.9
≤ 5 kg
78 (79%)
> 5 kg
21 (21%)
T Stage
T1/T2
T3/T4
N Stage
NX/N0/N1
N2
N3
Tumor Site
Oral cavity/oropharynx
Oral Cavity
Oropharynx
Larynx/hypopharynx
Larynx
Hypopharynx
Radiotherapy Dose-Intensity
delivered (BED)
Mean
Median
Range

18 (18%)
81 (82%)

2.8
112 (86%)
19 (14%)
39 (30%)
92 (70%)

47 (47%)
42 (42%)
10 (10%)

63 (48%)
58 (44%)
10 ( 8%)

Of these 230 patients, 99 patients (cases) had severe late toxicity and
131 patients (controls) did not have severe late toxicity. This results in
a crude rate of late toxicity of 43%. It should be noted that if the entire
population of patients (N=479) from all three studies are analyzed (as is
often performed for studies of late effects) the crude rate would appear
to be 21%., considerably lower than the data reported here. An actuarial
plot of “Time to Severe Late Toxicity” for all 230 evaluable patients is
shown in Figure 1.
100

75

50

25

0
Pts. at Risk
for Case 230

12

24

36

48

60

72

17

11

Months From Randomization
174

143

81

36

Figure 1. Time to Severe Late Toxicity Events – All Evaluable Patients.
42
7
35
57
41
16

(42%)
(7%)
(35%)
(58%)
(41%)
(16%)

115 Gy
117 Gy
67-117 Gy

71
5
66
60
51
9

(54%)
(4%)
(50%)
(46%)
(39%)
(7%)

116 Gy
117 Gy
111-126 Gy

Neck Dissection after RT
Yes
No

26 (26%)*
73 (74%)

21 (16%)
110 (84%)

Chemotherapy dose-intensity
delivered
< 85%
≥ 85%

22 (22%)
77 (78%)

29 (22%)
102 (78%)
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The original, potential patient population from these three studies was
479. However, there were 130 patients excluded because of local-regional
failure or death due to cancer, 100 patients excluded because of severe
pre-treatment laryngopharynx dysfunction due to tumor, 13 patients
excluded because of missing data, and 6 patients excluded because of
early death due to acute toxicity (see Table 1);. Thus, the overall evaluable
sample size for this report was 230 patients. The median followup for the
patient population is 2.96 years.

0

*Two of these patients had their neck dissection after experiencing a severe late toxicity

36

Results

% Failed

Table 2. Summary of patients with severe late toxicities (cases)
and patients without severe late toxicities (controls)

Table 3. Types of late toxicity events seen by trial
91-11
Feeding Tube Dependence
> 2 yrs. Post RT
Grade 3+ Pharyngeal
Dysfunction (RTOG late
toxicity criteria)
Grade 3+ Laryngeal
Dysfunction (RTOG late
toxicity criteria)
Death
Other (e.g. infection, fistula)
Any
No Severe late toxicity
event (controls)

97-03

—*

99-14
29*

Total
29

16

28

19

63

22

6

0

28

9
0
40**
62

2
1
21**
19

11
3
38**
50

* Feeding tube data were not collected at all in RTOG 91-11.
** Numbers do not always add up along columns, due to some patients having more than one
toxicity event.

22
4
99**
13

RTOG Analysis

Figure 2. Time to Severe Late Toxicity Subgoup Analyses based
on Patient/Treatment Characteristics
(All graphs exclude 2 patients who had neck dissection after already
experiencing a severe late toxicity.)

Patients with severe toxicities (cases) were more likely to be older and/or
to have larger T-stage and/or larynx/hypopharynx primary cancer. On
univariate analysis, there were no statistically significant differences in
the rates of late effects based on each individual study/arm.

100

Failed/Total
T1/T2
T3/T4

% Failed

75

17 / 56
80 / 172

50

25

0
0
Pts. at Risk
Case
56
Control 172

12

24

36

48

60

72

2
15

2
9

Months From Randomization
47
127

41
102

27
54

8
28

The pre-treatment characteristics of these 230 patients are shown in Table
2, including both pre-treatment and treatment-related characteristics.
Table 3 shows an accounting of the types of late toxicity events observed
in this analysis; most were related to swallowing function (particularly in
RTOG 97-03 and RTOG 99-14) or laryngeal dysfunction (RTOG 91-11).

Figure 2a. Time to Severe Late Toxicity by T stage Advanced T
stage is associated with a higher likelihood of severe late toxicity
(p value from Gray’s Test =0.031).

Univariate logistic regression analysis of pre-treatment and treatmentrelated variables is shown in Table 4. Actuarial estimates of time to
severe late toxicity as a function of T-stage, primary tumor site, and
neck dissection are shown in Figures 2a to 2c, respectively. The most
significant pre-treatment factor associated with severe late toxicity was
age, analyzed as a continuous variable (p=0.0038) – older patients were
significantly more likely to have severe late toxicity. T-stage (T3-4 more
likely to have severe late toxicity) and tumor site (larynx/hypopharynx
more likely to have severe late toxicity) were also statistically significant
factors. On univariate analysis, none of the treatment-related variables
were statistically significant except BED (p<0.0001), with a paradoxical
negative association between BED and severe late toxicity. The p-value
for potential association between severe late toxicity and neck dissection
after RT was 0.145.
The results of a multivariable logistic regression model analysis are
shown in Table 4. Age, T-stage and tumor site remained statistically
significant. In addition, a positive association between post-treatment
neck dissection and severe late toxicity was noted (p=0.02). Specifically,
out of the 230 patients in this study, 47 (20%) underwent post-treatment
neck dissection; this included 22% of the oral cavity/oropharynx patients
and 19% of the larynx/hypopharynx patients. These 47 patients had a

100

100

Failed/Total
Oral cavity/oropharynx
Larynx/hypopharynx

42 / 113
55 / 115

Yes ND
No ND

75

% Failed

% Failed

75

Failed/Total

50

25

24 / 45
73 / 183

50

25

0

0
0

Pts. at Risk
Case
115
Control 113

12

24

36

48

60

72

Months From Randomization
81
93

64
79

43
38

31
5

17
0

11
0

Figure 2b. Time to Severe Late Toxicity by Primary Tumor Site
Larynx/Hypopharynx cancer is associated with a statistically
non-significant higher likelihood of severe late toxicity (p value
from Gray’s Test =0.076).

0
Pts. at Risk
Case
45
Control 183

12

24

36

48

60

72

3
14

2
9

Months From Randomization
30
144

25
118

15
66

4
32

Figure 2c. Time to Severe Late Toxicity by Neck Dissection
Neck dissection is associated with a statistically non-significant
higher likelihood of severe late toxicity (p-value from Gray’s
Test =0.09).
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Table 4. Univariate and Multivariable Logistic Regression
Models to Identify Covariates that are associated with
severe late toxicity.
Univariate
Analysis

Covariates

Odds
Ratio

p-value

Age
Continuous variable

1.043*

0.0038

Gender
Female
Male

RL
1.140

0.6846

Multivariate
Analysis
95%
Odds confidence
Ratio Interval p value
1.05*

[1.02,1.09]

0.001

crude rate of severe late toxicity of 55% (compared with 40% for the 183
patients who did not undergo neck dissection).
Of note, besides neck dissection, other treatment-related factors were
not associated with severe late effects. Although the most aggressive
radiotherapy fractionation trial (RTOG 99-14, which used concomitant
boost XRT + cisplatin) numerically had the highest crude rate of
severe late toxicity (21/40 = 53%), there were no statistically significant
differences among the trial arms.
As noted in Table 4, radiotherapy dose delivered (as analyzed as
biologically equivalent dose [BED]) was significant on univariate analysis
(with a paradoxical relationship in which lower RT dose was associated
with higher risk) but fell out of the multivariable model. The amount of
chemotherapy delivered was not statistically significant in either model.

Discussion
Race
Non-Black
Black

RL
1.165

KPS
60-80
90-100

1.892
RL

0.0612

Hemoglobin (gm%)
Continuous Variable

1.005

0.9528

Weight loss (kg)
Continuous Variable

1.018

0.3733

T Stage
T1/T2
T3/T4

RL
2.041

0.0349

N Stage
NX/N0/N1
N2
N3

0.7458

RL
0.942
1.297

0.8464
0.6108

Tumor Site
Oral cavity/oropharynx RL
Larynx/hypopharynx 2.955

0.0131

BED (Toxicities)
based on Actual
Dose/Fx (Gy)
Continuous Variable

0.842

Neck dissection after RT**
Yes
1.632
No
RL
Percent of chemotherapy
received relative to the
protocol amount
< 85%
1.033
≥ 85%
RL

RL
3.07

RL
4.17

[1.444,6.54] 0.0036

[1.57,11.03] 0.0041

<0.0001

0.145

2.39
RL

[1.16,4.92]

0.018

0.9216

Abbreviations: RL=reference level; RT=radiation therapy
* The odds ratio of 1.043 for age indicates that for each one year increase in age, patients have 1.043 times
higher odds of being in the case group (having a severe late toxicity) than being in the control group (not
having a severe late toxicity).
** This excludes 2 patients who had neck dissection after having already experiencing a severe late toxicity.
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This retrospective analysis of several prospective trials shows that the rate
of severe late toxicity after CCRT for SCCHN is high, particularly with
the analysis methodology used here. Specifically, in this study, patients
with severe pre-treatment laryngopharynx dysfunction and patients
with early tumor recurrence were excluded a priori from this analysis.
Thus, the number of patients “at risk” for a severe late toxicity event
is much smaller than the original treated population. This technique
closely approximates the use of actuarial analysis of late complications,
a technique which yields a higher rate of complications than simply
reporting crude rate of complications, as reported by Bentzen et al.20
A true actuarial analysis of late complications in head and neck cancer
is difficult, because it is not easy to ascertain a date of onset of a late
complication in any one individual patient (Figures 2a-2c). Our sample
size of 230 patients makes this one of the largest studies of late toxicity in
the concurrent chemoradiotherapy era.
In this study, several factors that correlated with severe late toxicity were
identified. Since this is a retrospective study, the data must be considered
hypothesis-generating rather than definitive. Some caveats result from
the fact that these studies were conducted over a 10-year time period
(approximately 1991-2001), with variations in eligibility, treatment, and
data collection techniques. A second problem inherent to retrospective
studies like ours is that a number of potentially important factors may
not have been collected at all. For example our database does not include
information on tumor volume, cardiopulmonary co-morbidity, and
amount of tobacco consumed in followup.
However, it is logical to believe that age, tumor site and tumor stage
would predict for greater likelihood of severe late toxicity. The finding
that post-treatment neck dissection was significantly associated with
severe late toxicity was somewhat more surprising, although this has
been reported previously. The number of patients undergoing posttreatment neck dissection was relatively small (20%, despite over 50%
of the patients having N2-3 disease), and thus these data can not be
considered conclusive. It is possible that selection bias could lead to this
association; for example, patients with larger volume neck disease may
be more likely to undergo neck dissection and may be more likely to
have neck-tumor-related damage to adjacent normal tissues unrelated
to the neck dissection. It is possible, though, that disturbance of the soft
tissues of the neck via post-treatment neck dissection could cause added
swallowing dysfunction, for example by increasing fibrosis in the neck
and thus limiting the mobility of the laryngopharynx. It should be noted
that a similar report of an association between severe late toxicity and
post-treatment neck dissection was recently reported by researchers at

RTOG Analysis

Fox Chase Cancer Center21. If these findings are validated in additional,
larger datasets, there may be important implications with respect to the
controversy regarding neck dissection following chemoradiotherapy for
patients with advanced neck disease.
The lack of significant association between cumulative radiotherapy dose
delivery (or chemotherapy dose delivery) and severe late toxicity may
be due to the narrow dose range prescribed and the generally excellent
compliance. We are currently analyzing the detailed radiotherapy
records (simulation films, dosimetry and treatment records) available at
RTOG headquarters in order to estimate the doses received by individual
normal tissue sub-structures within the head and neck. Several recent
single-institution studies have rigorously analyzed the relationships
between radiotherapy dose-volume-histograms for normal structures
and the risk and severity of toxicities22, 23.
Considering the widespread acceptance of CCRT for SCCHN over the
last 10 years, there are relatively few detailed studies of late toxicities.
GORTEC reported long-term followup from their randomized trial of
radiotherapy alone versus 5-FU/carboplatin/radiotherapy for oropharynx
cancer; they did not find a significant difference in severe late toxicity24.
However, there were fewer than 50 long-term survivors in that study.
Staar reported that 51% of long-term survivors (> 2 years) after a very
intense combination of accelerated fractionation radiotherapy and
chemotherapy were dependent on feeding tubes8. With longer followup,
that alarmingly high rate did decrease, and was not significantly worse
than accelerated radiotherapy alone but the number of evaluable patients
was relatively small25. Shiley reported that 4 of 13 (31%) cancer-free
survivors (>1 year) after chemoradiotherapy required tube feedings for
some or all of their nutrition26.
These data suggest that the CCRT has reached the limits of acceptable
long-term toxicity. Dose intensity can not be easily increased without
some new and effective technique(s) of protection against late effects.
In the future, these may include modern techniques in radiotherapy
technology27, 28, or biopharmacologic radioprotectors29-31. Presently,
however, these techniques have only succeeded in reducing xerostomia,
not severe late dysphagia. Emphasis should therefore be on careful
patient selection for aggressive treatment and swallowing exercises before
during and after radiotherapy32, 33. Some patients may benefit from more
invasive procedures, such as dilatation of hypopharyngeal/esophageal
stricture under anesthesia.
For some patient subpopulations the risks of concurrent chemoradiotherapy may outweigh the benefits. For example, subgroup analysis of a
meta-analysis suggested that there was no significant survival benefit to
CCRT in patients older than age 701. Our data may add to the controversy
regarding management of the elderly patient with head and neck cancer
– if there is no significant survival benefit and a significant increase in
late toxicity with concurrent chemoradiotherapy, should it be the standard of care in this patient population?
Our study has several limitations that should be discussed. First, it is
a “meta-analysis” of three separate clinical trials, each of which had
somewhat different eligibility criteria, chemoradiotherapy regimen, and
year of activation. However, all of the patients did receive treatment that
would be considered appropriate standard of care in today’s oncology
clinic. Second, our exclusion of patients with pre-existing severe
laryngopharynx dysfunction from this analysis can be considered
controversial. Although patients were excluded a priori, determining
pre-existing severe laryngopharynx dysfunction is subjective. However,
it should be noted that the determination of post-treatment severe

laryngopharynx dysfunction (toxicity) is also subjective. It is extremely
difficult to determine if severe dysfunction after treatment is the result of
treatment or the result of the pre-existing cancer. By excluding patients
with pre-treatment severe laryngopharynx dysfunction, we attempted to
isolate the influence of treatment on outcomes. Third, our study is an
exploratory analysis; while it is one of the larger series on late toxicity
after chemoradiotherapy, the number of patients and number of events
are relatively small. We plan to address this in the future with an analysis
of the recently completed trial, RTOG 0129. This was a randomized trial
of standard fractionation versus accelerated fractionation radiotherapy
(with cisplatin in both arms). Preliminary acute and subacute toxicity
data showed no significant differences between the two arms34. It is
premature at this time to perform a detailed analysis of efficacy or late
toxicity from that study. It is possible that with improved knowledge
and experience with CCRT and supportive care available in the 21st
century, outcomes may be improved in RTOG 0129 compared to
historical controls.
Ultimately, it should be remembered that for most patients with head
and neck cancer, the highest priority is cure and length of survival35.
Excessive concern about treatment toxicity should not prevent the use of
proven aggressive multimodality treatment, provided the patient is well
informed about the potential late sequelae of these aggressive treatment
regimens.
References
1.

Bourhis J, LeMaitre A, Baujat B, et al. Individual patients’ data meta-analyses in head and neck
cancer. Curr Opin Oncol 2007;19(3):188-94.

2.

Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for
head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet
2000;355:949-55.

3.

Brizel DM, Albers MA, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent
chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;328:1798-804.

4.

Wendt TG, Grabenbauer CG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol
1998;16:1318-24.

5.

Calais G, Alfonsi M, Bardet E, et al. Randomized study comparing radiation alone RT versus
concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J
Natl Cancer Inst 1999;91:2081-6.

6.

Adelstein DA, Lavertu P, Saxton JP, et al. Mature results of a phase III trial comparing concurrent
chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell
carcinoma of the head and neck. Cancer 2000;88:876-83.

7.

Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy
and chemotherapy – a multicenter randomized trial. Int J Radiat Oncol Biol 2003;55:78-92.

8.

Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits
the additional benefit of simultaneous chemotherapy -- results of a multicentric randomized
German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71.

9.

Budach V, Stuschke M, Budach W., et al. Hyperfractionated accelerated chemoradiation with
concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated
accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the
radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective
randomized trial. J Clin Oncol 2005;23(6):1125-35.

10. Bensadoun RJ, Benezery K, Dassonville O, , et al. French multicenter phase III randomized study
testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF)
in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol
Biol Phys 2006;64(4):983-94.
11. Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck
cancer: overview of radiation morbidity. Clin Oncol (Royal Coll Radiol) 1997;9:308-12.
12. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in
patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a
systematic literature review. Radiother Oncol 2003;66:253-62.
13. Stuben G, Thews O, Pottgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol
2001;127:346-50.

BODINEJOURNAL

39

14. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ
preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
15. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group
97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-64.
16. Ang KK, Harris J, Garden A, et al. Concomitant boost radiation plus concurrent cisplatin for
advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J
Clin Oncol 2005;23(13):3008-15.
17. Garden AS, Pajak, T., Vokes, E., Forastiere, A., Ridge, J., Jones, C., Horwitz, E., Glisson, B., Nabell,
L., Cooper, J., Demas, W., Gore, E. Preliminary results of RTOG 9703 – A Phase II Randomized
Trial of Concurrent Radiation (RT) and Chemotherapy for Advanced Squamous Cell Carcinomas
(SCC) of the Head and Neck (abstr.). In: Proc Am Soc Clin Oncol (ASCO); 2001; San Francisco;
2001.
18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley
& Sons; 1980:167-169.
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk.
Ann Statist. 1988; 16: 1141-1154.
20. Bentzen SM, Vaeth M, Pedersen DE, Overgaard J. Why actuarial estimates should be used in
reporting late normal tissue effects of cancer treatment . . . now! Int J Radiat Oncol Biol Phys
1995;32(5):1531-4.
21. Lango M, Ende K, Ahmad S, Feigenberg SJ, Ridge JA. Neck dissection following organ preservation protocols prolongs feeding tube dependence in patients with advanced head and neck cancer
(abstr. #5525). In: 2006 ASCO annual meeting; 2006; Atlanta: J Clin Oncol; 2006.
22. Dornfeld K, Simmons JR, Karnell L, et al. Radiation doses to structures within and adjacent to the
larynx are correlated with long-term diet- and speech-related quality of life. Int J Radiat Oncol Biol
Phys 2007;68(3):750-7.
23. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for
head and neck cancer: which anatomic structures are affected and can they be spared by IMRT?
Int J Radiat Oncol Biol Phys 2004;60:1425-39.
24. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French head and neck oncology and
radiotherapy group randomized trial coparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22(1):69-76.
25. Semaru R, Mueller RP, Stuetzer H, Staar S, et al. Efficacy of intensified hyperfractionated and
accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-0fluorouracil:
updated results of a randomized multicentric trial in advanced head and neck cancer. Int J Radiat
Oncol Biol Phys 2006;64(5):1308-16.
26. Shiley SG, Hargunani C, Skoner JM, et al. Swallowing function after chemoradiation for advanced
stage oropharyngeal cancer. Otolaryngol Head Neck Surg 2006;134(3):455-9.
27. Bucci MK, Bevan A, Roach Mr. Advances in radiation therapy: conventional to 3D, to IMRT, to
4D, and beyond. CA Cancer J Clin 2005;55(2):117-34.
28. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer
aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J
Radiat Oncol Biol Phys 2007;2007:in press.
29. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad spectrum
radioprotector. Oncologist 2007;12(6):738-47.
30. Ning S, Shuii C, Khan WB, al. e. Effects of keratinocyte growth factor on the proliferation and
radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat
Oncol Biol Phys 1997;40:177-87.
31. Greenberger JS, Epperly MW. Review: antioxidant gene therapeutic approaches to normal tissue
radioprotection and tumor radiosensitization. In Vivo 2007;21:141-6.
32. Mittal BB, Pauloski BR, Haraf DJ, et al. Swallowing dysfunction – preventative and rehabilitation
strategies in patients with head and neck cancers treated with surgery, radiotherapy and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys 2003;57(5):1219-30.
33. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after
chemoradiation for head and neck cancer. J Clin Oncol 2006;24(17):2636-43.
34. Ang KK, Pajak T, Rosenthal D, et al. A phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129):
Report of compliance and toxicity. Proc. Am. Soc. Ther Rad Onc (ASTRO), 2007 Annual Meeting,
Los Angeles, IJRBOP suppl.
35. List MA, Stracks J, Colangelo L, et al. How do head and neck cancer patients prioritize treatment
outcomes before initiating treatment? J Clin Oncol 2000;18(4):877-84.

40

BODINEJOURNAL

Departmental Information
Thomas Jefferson University
Jefferson Medical College
Department of Radiation Oncology
Kimmel Cancer Center – Bodine
111 S. 11th Street
Philadelphia, PA 19107
Telephone: 215-955-6700
www.kimmelcancercenter.org/kcc/radonc/bodine.htm

FACULTY
Clinicians
Adam P. Dicker, MD, PhD
Interim Chair
P. Rani Anné, MD
Jessie W. DiNome, MD
Scot A. Fisher, DO
Eric L. Gressen, MD
Arthur J. Harvey, MD
Alexander Lin, MD
Mitchell Machtay, MD
Jeffrey Rosenstock, MD
Shari B. Rudoler, MD
Merrill J. Solan, MD
Richard K. Valicenti, MD
Maria Werner-Wasik, MD

Division of Experimental
Radiation Oncology
Adam P. Dicker, MD, PhD
Division Director

Division of Medical Physics
Yan Yu, PhD, MBA
Division Director
Jungshen Cao, MS
Lei Fu
James M. Galvin, DSc
Amy Harrison, MS
Jun Li, PhD
Haisong Liu, PhD
Harold Perera, PhD
Tarun Podder, PhD
Ying Xiao, PhD

Ronald A. Coss, PhD
Dennis B. Leeper, PhD
Qing Ren, MD, PhD
Marlene Rochas DeQuadros, PhD
Phyllis R. Wachsberger, PhD

BODINEJOURNAL

41

Research
Department of Radiation Oncology
Clinical Research Studies/Grants
• Phase I Study of Combination of Sorafenib and Radiation
Therapy For The Treatment of Patients With Brain
Metastases and Primary Brain Tumors
• A Phase I Pilot Study of Samarium-153 Combined with
Neoadjuvant Hormonal Therapy and Radiation Therapy in
Men with Locally Advanced Prostate Cancer
• A Phase I Study of Pemetrexed (Alimta) and Carboplatin
and Radiation Therapy in Patients with Inoperable NonSmall Cell Lung Cancer
• A Phase I Study of Combination Chemo-radiotherapy with
Biologic Therapy for Advanced Head and Neck Cancer
[Bevacizumab IND #12,907] Original: 1/26/06; Revised
3/24/06)
• A Randomized, Phase III, Open-Label Study of Oral
Topotecan Plus Whole Brain Radiation Therapy (WBRT)
Compared with WBRT Alone in Patients with Brain
Metastases From Non Small Cell Lung Cancer HYT105962,
Division: Worldwide Development, Retention Category:
GRS019, Protocol Amendment Number: 01, Compound
Number: SK&F-104864, Effective Date: 11-Apr-2007;
including a Topotecan Oral Investigator Brochure,
Compound Number: SK&F-104864, Approved Name:
Hycamtin, Effective Date: 13-Jul-2006, Version number:8
dated July 2006
• Prospective, Longitudinal, Multi-Center, Descriptive
Registry of Patients Receiving Therapy Other Than Surgical
Resection Alone for Newly Diagnosed Head and Neck
Carcinoma.
• A Phase 1, Open-Label, Dose-Escalation, Safety Study of
the Combination of VELCADE and Chemoradiation for the
Treatment of Patients with Cancer
• A Phase II Evaluation of Dose-Painted IMRT in
Combination with 5-Fluorouracil and Mitomycin-C
for Reduction of Acute Morbidity in Carcinoma of the
Anal Canal
• A Randomized Prospective Active-controlled Study of
the Epi-Rad90TM Opthalmic System for the Treatment of
Subfoveal Choroidal Neovascularization Associated With
Wet Age-related Macular Degeneration
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• A Phase IB, Open-Label, Dose-escalation Safety Study of the
Combination of Sunitinib and Radiation for the Treatment
of Patients with Cancer.
• A Pilot Study Investigating Active Breathing Control (ABC)
to Reduce Radiation Dose to Normal Structures in Breast
Cancer Patients
• A Randomized Trial Comparing Two Forms of
Immobilization of the Head for Fractionated Stereotactic
Radiotherapy
• Phase I Dose Escalation Trial in Patients with Brain
Metastases Using IMRT
• Exploratory Study of the Efficacy of the Cone Beam
Computed Tomography (CBCT) Scanning During Radiation
Therapy for Tumors of the Head and/or Neck
• A Phase III Protocol of Androgen Suppression (AS) and
Radiation Therapy (RT) vs Androgen Suppression and RT
Followed by Chemotherapy With Paclitaxel, Estramustine
and Etoposide (TEE) for Localized, High Risk Prostate
Cancer
• Waterfall Plots After Stereotactic Radiotherapy for Acoustic
Neuroma: Assessing Response With a Novel Metric of
Treatment Efficacy
• Stereotactic Fractionated Radiotherapy and Radiosurgery
for the Treatment of Chordomas and Chondrosarchomas
• Retrospective Study of Esophageal Cancer Patients Treated
With Surgery, Radiation Therapy, Chemotherapy Or Any
Combination of the Three At Thomas Jefferson University
Hospital
• Optimization of Radiation Therapy for Hypopharyngeal and
Cervical Esophageal Cancers: A Comparison of Conventional
and Three-dimensional Conformal Techniques
• Retrospective Analysis of Radiation Dose to Optic
Structures Using Fractionated Stereotactic Radiotherapy:
Determination of a Dose/Volume Relationship to Guide
Safe Treatment of Tumors Near the Optic Apparatus
• Standardize Serum and Plasma Sample Collection and
Cytokine Normal Values for RTOG Repository and
Database

Research

• A Prospective Phase II Trial of Transperineal Ultrasound-guided
Brachytherapy for Locally Recurrent Prostate Adenocarcinoma
Following External Beam Radiotherapy – RTOG 0526

or 5 Fluorouracil and Cisplatin Followed by Selective Bladder
Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant
Chemotherapy

• A Phase III Double Blind Placebo Controlled Study To Evaluate
the Efficacy of Zometa for the Prevention of Osteoporosis and
Associated Fractures In Patients Receiving Radiation Therapy
and Long Term LHRH Agonists For High-grade and/or Locally
Advanced Prostate Cancer – RTOG 0518

• RTOG #0236: A Phase II Trial of Stereotactic Body Radiation
Therapy (SBRT) in the Treatment of Patients with Medically
Inoperable Stage I/II Non Small Cell Lung Cancer

• RTOG #0012: A Randomized Phase II Trial of Preoperative
Combined Modality Chemoradiation for Distal Rectal Cancer
• RTOG #0024: A Phase II Trial of Early Postoperative Paclitaxel
Followed by Paclitaxel and Cisplatin Concurrent With Radiation
Therapy for Resected, High-Risk Squamous Carcinoma of the
Head and Neck
• RTOG #0126: A Phase III Randomized Study of High Dose
3D-CRT in Patients Treated for Localized Prostate Cancer
• RTOG #0129: A Phase III Trial of Concurrent Radiation and
Chemotherapy for Advanced Head and Neck Carcinomas
• RTOG #0132: A Phase II Trial of Neoadjuvant/Adjuvant STI-571
(Gleevec NSC #716051) for Primary and Recurrent Operable
Malignant Gist Expressing the Kit Receptor Tyrosine Kinase
(CD117) (ACRIN 6665)
• RTOG #0211: A Phase I/ Study of an Oral Epidermal Growth
Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TK), ZD
1839 (IRESSA) (NSC #715055) With Radiation Therapy in
Gliblastoma Multiforme
• RTOG #0214: A Phase III Comparison of Prophylactic Cranial
Irradiation in Patients with Locally Advanced Non-Small Cell
Lung Cancer
• RTOG #0225: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal
Cancer
• RTOG #0227: A Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and
Post-Irradiation Temozolomide for Primary Central Nervous
System Lymphoma
• RTOG #0232: A Phase III Study Comparing Combined External
Beam Radiation and Transperineal Interstitial Permanent
Brachytherapy with Brachytherapy Alone for Selected Patients
with Intermediate Risk Prostatic Carcinoma
• RTOG #0233: A Phase II Randomized Trial for Patients with
Muscle-Invading Bladder Cancer Evaluating Transurethral
Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin

• RTOG #0241: A Phase I Study Of Irinotecan And Cisplatin In
Combination With Twice Daily Thoracic Radiotherapy (45 Gy)
or Once Daily Thoracic Radiotherapy (70 Gy) for Patients with
Limited Stage Small Cell Lung Cancer
• RTOG #0247: A Randomized Phase II Trial of Neoadjuvant
Combined Modality Therapy for Locally Advanced Rectal
Cancer (Version: Activation 3/15/04)
• RTOG #0320: A Phase III Trial Comparing Whole Brain
Radiation and Stereotactic Radiosurgery Alone Versus With
Temozolomide or Erlotinib in Patients with Non-Small Cell
Lung Cancer and 1-3 Metastases
• RTOG #0415: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3DCRT/IMRT in Patients with Favorable-Risk Prostate Cancer
• RTOG #0420: A Phase II Study of Radiation Therapy Plus
Low Dose Temozolomide Followed by Temozolomide Plus
Irinotecan for Glioblastoma Multiform
• RTOG #0521: A Phase III Protocol of Androgen Suppression
(AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by
Chemotherapy with Docetaxel and Prednisone for Localized,
High-Risk Prostate Cancer
• A Randomized Phase III Trial of Concurrent Accelerated
Radiation and Cisplatin Versus Concurrent Accelerated
Radiation, Cisplatin, and Cetuximab (C225) [Followed by
Surgery for Selected Patients] For Stage III and IV Head and
Neck Carcinomas
• RTOG #0524: A Phase I/II Trial of a Combination of Paclitaxel
and Trasuzumab with Daily Irradiation or Paclitaxel Alone with
Daily Irradiation Following Transurethral Surgery for NonCystectomy Candidates with Muscle Invasive Bladder Cancer
• RTOG #0525: A Phase III Trial Comparing Conventional
Adjuvant Temozolomide with Dose-Intensive Temozolomide
in Patients with Newly Diagnosed Glioblastoma
• RTOG #0611-Urinary VEGF and MMP levels in patients
receiving radiation therapy for glioblastoma multiforme:
Prospective determination of a predictive value for recurrence
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• A Randomized Phase III Comparison of Standard-Dose
(60Gy) Versus High Dose (74Gy) Conformal Radiotherapy
with Concurrent and Consolidation Carboplatin/Paclitaxel
in Patients with Stage IIIA/IIIB Non Small Cell Lung Cancer;
RTOG #0617/NCCTG N0628/CALGB 30609; Version Date:
August 1, 2007; Updated Date: November 27, 2007; Activation
Date: November 27, 2007

• RTOG #9601: A Phase III Trial of Radiation Therapy With or
Without Casodex in Patients with PSA Elevation Following
Radical Prostatectomy for pT3NO Carcinoma of the Prostate

• RTOG #9003: A Phase III, Randomized Study to Compare
Twice Daily Hyperfractionation, Accelerated Hyperfractionation
With a Split and Accelerated Fractionation With Concomitant
Boost to Standard Fractionation Radiotherapy for Squamous
Cell Carcinomas of the Head and Neck

• RTOG #9708: A Phase II Study of Adjuvant Postoperative
Irradiation Combined With Cisplatin/Taxol Chemotherapy
Following TAH/BSO for Patients With High-risk Endometrial Cancer

• RTOG #9019: A Phase III Study of the Treatment of Pathologic
Stage C Carcinoma of the Prostate with Adjuvant
Radiotherapy
• RTOG #9202: A Phase III Trial of the Use of Long-Term Total
Androgen Suppression Following Neoadjuvant Hormonal
Cytoreduction and Radiotherapy in Locally Advanced
Carcinoma
• RTOG #9403: A Postoperative Evaluation of 5-FU By Bolus
Injection vs. 5-FU By Prolonged Venous Infusion Prior to
and Following Combined Prolonged Venous Infusion + Pelvis
XRT vs. Bolus 5-FU + Leucovorin + Levamisole Prior to and
Following Combined Pelvic XRT +Bolus 5-FU + Leucovorin in
Patients with Rectal Cancer, Phase III
• RTOG #9406: A Phase I/II Dose Escalation Study Using
Three Dimensional Conformal Radiation Therapy for
Adenocarcinoma of the Prostate
• RTOG #9408: A Phase III Trial of the Study of Endocrine
Therapy Used as a Cytoreductive and Cytostatic Agent Prior
to Radiation Therapy in Good Prognosis Locally Confined
Adenocarcinoma of the Prostate
• RTOG #9410: A Three-Arm, Phase III Study of Concomitant
vs. Sequential Chemotherapy and Thoracic Radiotherapy for
Patients With Locally Advanced Inoperable Non-Small Cell
Lung Cancer
• RTOG #9413: A Phase III Trial Comparing Whole Pelvic
Irradiation Followed by a Conedown Boost to Boost Irradiation
Only and Comparing Neoadjuvant to Adjuvant Total Androgen
Suppression (TAS)
• RTOG #9501: A Phase III Intergroup Trial of Surgery Followed
by Radiotherapy vs. Radiochemotherapy for Resectable High
Risk Squamous Cell Carcinoma of the Head and Neck
• RTOG #9512: A Randomized Study of Hyper-Fractionation vs.
Conventional Fractionation in T2 Squamous Cell Carcinoma of
the Vocal Cord
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• RTOG #9703: A Randomized, Phase II Trial of Concurrent
Radiation and Chemotherapy for Advanced Squamous Cell
Carcinomas of the Head and Neck

• RTOG #9712: A Phase I/II Dose Escalation Study of Thoracic
Irradation with Concurrent Chemotherapy for Patients with
Limited Small Cell Lung Cancer
• RTOG #9801: A Phase III Study of Amifostine Mucosal
Protection for Patients With Favorable Prognosis Inoperable
Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving
Sequential Induction and Concurrent Hyperfractionated
Radiotherapy for Paclitaxel and Carboplatin
• RTOG #9802: A Phase II Study of Observation in Favorable
Low-Grade Glioma and a Phase III Study of Refraction
with or without PCV Chemotherapy in Unfavorable LowGrade Glioma
• RTOG #9803: A Phase I/II Dose Escalation Study Applying
Conformal Radiation Therapy in Supratentorial Glioblastoma
Multiforme
• RTOG #9805: A Phase II Trial of Transrectal Ultrasound
Guided Permanent Radioactive Implantation of the Prostate
for Definitive Management of Localized Adenocarcinoma of
the Prostate
• RTOG #9811: A Phase III, Randomized Study of 5-FU,
Mitomycin-C and Radiotherapy vs. 5-FU, Cisplatin and
Radiotherapy in Carcinoma of the Anal Canal
• RTOG #9813: A Phase I/III Randomized Study of Radiation
Therapy and Temozolomide vs. Radiation Therapy and BCNU
for Anaplastic Astrocytoma
• RTOG #9906: A Phase I/II in Patients With Muscle-Invading
Bladder Cancer of Transurethral Surgery Plus Taxol,
Cisplatin and BID Irradiation Followed by Either Selective
Bladder Preservation or Radical Cystectomy and Adjuvant
Chemotherapy
• RTOG #9910: A Phase III Trial to Evaluate the Duration
of Neoadjuvant Total Androgen Suppression and Radiation
Therapy in Intermediate-Risk Prostate Cancer

Research

• RTOG #0235: Positron Emission Tomography Pre and Post
Treatment Assessment for Locally Advanced Non Small Cell
Lung Cancer (ACRIN #6668)
• RTOG #0413: A Randomized Phase III Study of Conventional
Whole Breast Irradiation (WBI) versus Partial Breast Irradiation
(PBI) for Women with Stage 0, I, II Breast Cancer (NSABP B-39)
• RTOG #0615: Phase II Study of Concurrent Chemoradiotherapy using Three-Dimensional Conformal Radiotherapy
(3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT)
+ Bevacizumab (BV) for Locally or Regionally Advanced
Nasopharyngeal Cancer
• RTOG #0019: A Phase II Study of External Beam Radiation
Therapy Combined With Permanent Source Brachytherapy for
Intermediate Risk Clinically Localized Adenocarcinoma of the
Prostate
• RTOG #0212: A Phase II/III Randomized Trial of Two Dose
Schedules for Delivering Prophylactic Cranial Irradiation for
Patients with Limited Disease Small Cell Lung Cancer
• A Phase II Randomized Trial of Surgery Followed by
Chemoradiotherapy Plus C225 (CETUXIMAB) for Advanced
Squamous Cell Carcinoma of the Head and Neck
• A Phase III Trial for Locally Recurrent, Previously Irradiated
Head and Neck Cancer: Concurrent Re-Irradiation and
Chemotherapy Versus Chemotherapy Alone
• RTOG #0424: A Phase II Study of a Temozolamide-Based
Chemoradiotherapy Regimen for High Risk Low-Grade
Gliomas
• A Phase II Trial of Preoperative Chemotherapy and
Chemoradiotherapy for Potentially Resectable Adenocarcinoma
of the Stomach

Basic Research Studies/Grants

• Ethyl Pyruvate As A Radiation Mitigator – In Vivo Characterization And Mechanistic Studies
• Multichannel Robotic System for Concurrent Delivery and
Immobilization of Interstitial Therapeutic Agents
• Molecular Determinants of Glioblastoma Response to ZD6474
Combined With Radiotherapy And Temozolamide
• Improvement of Fractionated Radiation Therapy by Combination with SU11248 - Impact of Scheduling
• Molecular Determinants of Glioblastoma Response to AZD2171
Combined with Radiotherapy and Temozolamide
• Molecular Determinants of Glioblastoma Response to BAY
43-9006 (Sorafenib) Combined with Temozolamide and
Radiotherapy
• RTOG Research Associates Committee Chair
• RTOG Group Member Agreement
• Fused MR-Based Imaging Datasets Improving Surgical
Outcomes and Providing Superior Response Classification
System of Malignant Gliomas

Translational Research Studies/Grants
• Clinical Utility of Biomarkers for Stage III Non-small Cell Lung
Carcinoma and Stage IV Head and Neck Cancer
• Checkpoint Reduced Cell Sensitivity to High Energy ParticlesInduced Killing
• Characterization of the Role of Fhit In Maintenance of Genomic
Integrity Following Low Dose Radiation, In Vivo and In Vitro
• Modification of Hyperthermia Response: Project 1 “Sensitization to Thermoradiotherapy in Human Melanoma
Xenografts”

• Improvement of Tumor Control by Combining an Inhibitor
of the Epidermal Growth Factor Receptor (EGFR) with
Radiation Therapy

• Modification of Hyperthermia Response: Core B “Administration”

• A New Role of MEPE/OF45 as a Co-factor of CHK1 for DNA
Damage Response

• Modulation of Radiosensitivity in zebrafish

• A New Target for Preventing Breast Cancer Metastasis to Bone
• The Mechanism of Excess Relative Risk on Carcinogenesis
Induced High Let Radiation
• ACRIN Protocol 6688: PET Pre- and Post Treatment Assessment
for Locally Advanced Non-Small Cell Lung Carcinoma

• Radiation Therapy Oncology Group Committee Chair

• Radiation Therapy Oncology Group Physicist Chair
• An Emerging Technology Assessment Mechanism for RTOG
Protocols
• Modification of Hyperthermia Response: Project 3 “Reduced
pHi Inhibits Heat-Induced HSP, Enhances Apoptosis”
• Modification of Hyperthermia Response: Core A “Intracellular
pH Regulation”
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• Deputy Group Chair of the Radiation Therapy Oncology Group
• Protection from Dose Limiting Toxicity of Chemoradiation for
Head and Neck Cancer
• Improvement of Tumor control by Combining a VEGF Blocker,
VEGF-Trap, with Radiation Therapy
• Molecular Signatures related to Amifostine Radioprotection
• Evaluation of Fullerene Nanoparticles in a Zebrafish Model
• Microenvironmental control of the Radiation Response
• Vice Chair Translational Research Program
• Nutrigenomics for the Study of Disease Prevention and Intervention
• Protection from Dose Limiting Toxicity of Chemoradiation for
Head and Neck Cancer
• Health Research Formula Fund Grant Project 1: Clinical Utility
of Biomarkers for Stage III Non-small Cell Lung Carcinoma
and Stage IV Head and Neck Cancer
• Enhancement of Tumor Response to Radiation by Use of
Vascular Targeting Agent, ZD6126
• Conducting Biomarker, and Proteomics Correlative Research
in the Radiation Therapy Oncology Group
• Microenvironmental Control of the Radiation Response After
ERBITUX Blockade
• Improvement of Colorectal Tumor Control by Combining
ERBITUX with Radiotherapy and Chemotheraputic Agents
Oxaliplatin and Irinotecan (CPT-11) PCGA 04-001
• Improvement of Brain Tumor Control by Combining
ERBITUX with Radiotherapy and Chemotherapeutic Agents
Temozolamide (CPT-11) PCGA 04-025
• Orthogonal Ultrasound for Cancer Detection and Therapy
• Sono-Contrast Induced Functional Imaging/Spectroscopy
• Robot-Assisted Platform for Intratumoral Delivery
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Support Groups
Jefferson Kimmel Cancer Center Support Groups, October – December 2008
October
4

A Place for Me
A program for children whose parent or grandparent has
cancer. Using art, games and other activities,
children are helped to understand and to cope with the
diagnosis of cancer in the family. A separate group for
parents or grandparents is held concurrently.
Time:
10 am – 1:30 pm
Location: Bluemle Life Sciences Building

15

The Delaware Valley Brain Tumor
Support Group
Time:
7 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105

17

Brain Tumor Caregiver Workshop
Time:
8 am – 4 pm
Location: Bluemle Life Sciences Building, Suite 101

23

Facing Breast Cancer
Screening and Detection
Barbara C. Cavanaugh, MD, Breast Imaging
Time:
12 – 1:30 pm
Location: Hamilton Building, Suite 505

25

Navigating the New Normal
(for young adult cancer survivors, ages 18-45)
Cartoon Boot Camp
Christian “Patch” Patchell, Graphic Artist
Time:
2 – 5 pm
Location: Hamilton Building, Suite 210/211

30

Current Topics
End-of-Life Issues
Anne Delengowski, RN, MSN, AOCN
Time:
12 – 1:30 pm
Location: Hamilton Building, Suite 505

November
3

6

13

Look Good…Feel Better
A free program for women who are undergoing cancer
treatment to learn to cope with appearance-related side
effects of treatment.
Time:
1:30 – 3:30 pm
Location: Gibbon Building, 2nd Floor, Suite 2135
Survivor’s Conference
Life After a Cancer Diagnosis
A patient and family conference on all issues
relating to cancer survivorship.
Time:
3:30 – 7 pm
Location: Bluemle Life Sciences Building
Current Topics
Lung Cancer Awareness Month Program
Benny Weksler, MD, Division of Cardiothoracic Surgery,
Section of Thoracic and Foregut Surgery
Time:
12:00 – 1:30 pm
Location: Hamilton Building, Suite 505

19

The Delaware Valley Brain Tumor
Support Group
Group for individuals diagnosed with a brain tumor and
their families. Patients and families share information,
gain insight and develop coping strategies to face the
challenges associated with living with a brain tumor. For
more information, call 215-955-4429.
Time:
7 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105

20

Current Topics
Jefferson Journaling: A Program for Women Facing
Cancer, Janet Ruth Falon
Time:
12:00 – 1:00 pm
Location: Kimmel Cancer Center
Bodine Building, Suite G-312

December
3

Navigating the New Normal
(for young adult cancer survivors, ages 18-45). Holiday
Happy Hour – an opportunity to network with other
survivors your age. $3.00 drink specials, free appetizers and
live music (non-alcoholic drinks also available). Friends,
partners and other supports are welcome to attend.
Time:
6 – 8 pm
Location: Doc Watson’s Pub, 216 S. 11th Street
2nd Floor

11

Man to Man
PSA Rising Post-Treatment
Leonard G. Gomella, MD
Chair and Professor, Department of Urology
Time:
12:00 – 1:30 pm
Location: Bluemle Life Sciences Building, Suite 101

17

The Delaware Valley Brain Tumor
Support Group
Time:
7:00 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105

Ongoing Programs
Every Thursday
Radiation Therapy Information Session
Time:
10 – 11:00 am
Location: Kimmel Cancer Center – Bodine, Suite G-312
Learning to Live Better with the Stress of Cancer Research
Study
Free 8-week cancer support programs for women,
21 years or older, and diagnosed with cancer or
recurrence within three years. Call 215-955-2881 or
1-800-JEFF-NOW, or visit: www.JeffersonHospital.org/
cim and click on the study poster.
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An outstanding new title
from Informa Healthcare

Image-guided Radiation
Therapy For Prostate Cancer:
Principles And Practice
Richard K. Valicenti
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, U.S.A.
Adam P. Dicker
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, U.S.A.
David A. Jaffray
Princess Margaret Hospital, Toronto
Ontario, Canada
May 2008 / ISBN-13: 9781420060782
312 pp. / 158 Illustrations / Price: $229.95

Answering the need that exists for a single reference to
address the practical issues of implementing image guided
radiation therapy (IGRT) into prostate cancer treatment,
this text provides:

Contents Include:
• Overview and treatment guidelines for image-guided
treatment in prostate cancer management
• Imaging modalities

• complete overview of new and exciting technologies

• Modeling potential benefits from IGRT

• practical guidance on successfully employing IGRT to
improve patient outcomes

• Pelvic and prostate anatomy, implications for IGRT

• disease stage-specific recommendations which include
dosage, fractionation, target volume delineation, and
tissue tolerances
• latest novel approaches to radiotherapy of prostate
cancer that include intensity modulated radiation
therapy (IMRT), hypofractionated radiation therapy,
and proton beam radiation therapy

• Image-guided treatment planning and localization
modalities
• Image-guidance: the urologist perspective
• IGRT in prostate cancer: focus on fiducials
• IGRT in prostate cancer: focus on BAT and ultrasound
• IGRT in prostate cancer: focus on adaptive therapy
• IGRT in postoperative RT for prostate cancer
• The use of image-guidance in prostate brachytherapy
• IGRT in prostate cancer: targeting pelvic lymph nodes
• Fractionation issues with IGRT for clinically localized
prostate cancer
• Image-guided proton beam radiotherapy
• Future developments: On-line dosimetric verification
and cone-beam RT planning and verification
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